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1Circulating lipid and lipoprotein biomarkers have consis-tently been associated with cardiovascular diseases as 
myocardial infarction and stroke.1 A previous meta-analysis 
of low-density lipoprotein cholesterol (LDLC)–lowering tri-
als has shown risk reduction for ischemic stroke.2 In addi-
tion, the SPARCL trial (Stroke Prevention by Aggressive 
Reduction in Cholesterol Levels) in secondary stroke preven-
tion demonstrated a significant reduction in recurrent stroke 
with atorvastatin.3 Importantly, it is unclear as to whether lipid 
lowering with statins is beneficial across different ischemic 
stroke subtypes. Although lipid lowering is likely to be effec-
tive in large artery atherosclerosis stroke, the evidence impli-
cating elevated lipids in the small artery occlusion stroke is 
scant. In the recent J-STARS (Japan Statin Treatment Against 
Recurrent Stroke)  stroke secondary prevention trial, pravas-
tatin reduced large artery atherosclerosis recurrent stroke risk, 
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but it had no effect on small artery occlusion risk.4 In addi-
tion, there is insufficient evidence whether high-density lipo-
protein cholesterol (HDLC) and triglycerides may be causally 
involved in the development of ischemic stroke.5
Genetic variants are randomly distributed at conception and 
thus can be used to overcome 2 of the major problems of obser-
vational studies, biases because of confounding and reverse 
causation. Mendelian randomization (MR) is an analytic 
method that leverages genetic variants associated with heritable 
risk factors to generate causal estimates between such factors 
and diseases. This method has recently been used to provide 
evidence for a causal relationship of LDLC and triglycerides 
with coronary artery disease (CAD). However, MR studies have 
not indicated any causality between HDLC and CAD.6–10
All MR studies rely on 3 basic assumptions: the genetic 
instrument (1) should be reliably associated with the expo-
sure, (2) should be associated with the outcome only through 
the exposure, and (3) should not be associated with other 
factors that affect the outcome. This means that the genetic 
variants used as instruments must exert their effects on the 
outcome exclusively through the exposure of interest and 
not through alternative pathways. Single genetic variants, as 
single nucleotide polymorphisms (SNPs), that fulfill the MR 
assumptions, can be used, but their use may only be meaning-
ful in large studies powerful enough to study the effect of the 
small proportion of exposures explained by the single vari-
ants. However, summary-level data of large meta-analyses of 
genome-wide association studies (GWAS) are increasingly 
available and allow the use of combinations of SNPs in MR 
analyses. However, SNPs may not fulfill the MR assumptions 
and may lead to bias through pleiotropic effects. Several meth-
ods have been recently developed to correct for such bias.11,12
We conducted an MR study, using summary-level data from 
publicly available GWAS of lipids and other cardiometabolic 
traits, to investigate the causal relationship of LDLC, HDLC, 
and triglycerides in the development of ischemic stroke as a 
whole and its 3 main subtypes: cardioembolic, large artery 
atherosclerosis stroke, and small artery occlusion.
Methods
Data Sources
Summary-level data for 185 genome-wide lipids-associated SNPs 
were obtained from the publicly available data through the Global 
Lipids Genetics Consortium.13 The Global Lipids Genetics Consortium 
GWAS included 188 577 individuals of primarily European ancestry. 
The summary-level data for ischemic stroke and its subtypes were 
obtained from the National Institute of Neurological Disorders and 
Stroke−Stroke Genetics Network.14 The Stroke Genetics Network 
GWAS included 16 851 ischemic stroke cases and 32 473 controls 
of predominantly European ancestry. Of the ischemic stroke cases, 
2410 were subclassified as large artery atherosclerosis stroke, 3186 
as small artery occlusion stroke, and 3427 as cardioembolic stroke 
using the Trial of Org 10172 in Acute Stroke Treatment criteria.15 The 
Global Lipids Genetics Consortium summary data were available in 
the public domain, and an ethics approval was obtained from each 
contributing study in the original publication.13 Each study included 
in the Stroke Genetics Network was approved by the local institu-
tional review board and ethics committee, and all participants pro-
vided written informed consent.14 In line with the Transparency and 
Openness Promotion Guidelines, data and analytic methods used 
have been appropriately cited, and the data used for the main analyses 
are provided in Tables I and II in the online-only Data Supplement.
SNP Selection
We obtained summary estimates for 185 SNPs reported in the most 
recent lipids GWAS by Willer et al13 to be associated with LDLC, 
HDLC, and triglycerides. The 185 SNPs can be considered as inde-
pendent because of low linkage disequilibrium (maximum r2<0.2 
between any SNPs). Each instrumental variable was constructed 
from SNPs showing GWAS significant association (P<5×10–8) with 
the respective trait. The instrumental variables included 76 SNPs for 
LDLC, 86 SNPs for HDLC, and 51 SNPs for triglycerides. The LDLC, 
HDLC, and triglycerides instruments explained 6.4%, 5.9%, and 4.6% 
of the variances in LDLC, HDLC, and triglycerides, respectively, as 
estimated by the gtx package in R. We then obtained summary esti-
mates for the same set of 185 SNPs from the Stroke Genetics Network 
GWAS for ischemic stroke and its subtypes, and the effect alleles were 
matched with all lipid and stroke summary data. Summary data on 2 
SNPs (rs1998013 and rs7422339) were missing.
Statistical Analysis
We performed 3 different MR analyses: (1) conventional inverse-
variance–weighted MR; (2) multivariable MR to adjust for pleiotropy 
using summary-level data of other known lipid- and cardiometabolic 
traits; and (3) MR-Egger to account for all pleiotropic bias from 
known and unknown factors.
First, we performed inverse-variance–weighted MR (hereafter 
referred to as conventional MR) using each set of SNPs for each trait 
as instrumental variables. This method is a weighted linear regression 
between the instrumental SNP-β estimates of each lipid trait as expo-
sure variables and the stroke β estimates of the same SNPs as out-
come variables. This regression is weighted by the inverse-variance 
of SNP–stroke association, and the regression line is fixed to zero. 
This method, however, does not correct for pleiotropic bias if pres-
ent.16 To correct for that, we performed inverse-variance–weighted 
multivariable MR (hereafter referred to as multivariable MR) using 
all 185 SNPs. This method adjusts for pleiotropic effects across the 
included lipid traits in our analyses using β’s from SNP–stroke as 
outcome variables and β’s from SNP-LDLC, SNP-HDLC, and SNP-
triglycerides as predictors in 1 multivariable model. The intercept was 
constrained to zero, and the regression was weighted by the inverse-
variance of the SNP–stroke associations.17 We additionally performed 
multivariable MR using a total of 343 SNPs (r2<0.2). In addition to 
the 185 primarily lipid associated SNPs, we included SNPs that asso-
ciate primarily with other cardiometabolic traits, including 97 SNPs 
for body mass index, 49 for waist-to-hip ratio adjusted for body mass 
index, 36 for fasting plasma glucose, and 26 for fasting plasma insu-
lin, all obtained from publicly available data releases of the latest 
GWAS meta-analyses.13,18–20 We additionally performed MR-Egger as 
previously described.12 Egger regression was previously developed 
to detect small-study bias in meta-analyses and can be similarly used 
to detect bias because of unbalanced pleiotropy in MR studies. In 
contrast to conventional MR, the regression line is unconstrained, 
and the intercept represents the average pleiotropic effects across all 
SNPs, assuming that the distribution of pleiotropic effects is inde-
pendent from the genetic associations with exposure, also known 
as the INstrument Strength Independent of Direct Effect assump-
tion. In addition to MR-Egger, we performed sensitivity analyses to 
minimize biases because of pleiotropy by excluding SNPs exhibit-
ing potential pleiotropy using Steiger filtering. Steiger filtering was 
performed using the 185 lipid-associated SNPs for each lipid trait. 
SNPs were excluded if they explained larger variance of any of the 
other 2 lipid traits compared with the trait of interest. We performed 
a 2-stage Steiger filtering. The first stage was based solely on the r2 
values of each SNP with respect to the 3 lipid traits. For example, 
for the LDLC instrument, we included an SNP if it had a larger r2 
value for LDLC compared with HDLC or triglycerides. In a stricter 
additional stage, SNPs were included only if r2 values were signifi-
cantly larger for the trait compared with the other 2 traits (P<0.05), 
as described before.21 Finally, analyses were done using instruments 
that only included SNPs that exclusively associated with the trait 
of interest and not with the other traits (P>5×10–8). We analyzed 
all of these instruments for outlier pleiotropy using MR-Pleiotropy 
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Residual Sum and Outlier test and performed conventional MR 
and MR-Egger after exclusion of outlier SNPs. Analyses were per-
formed using the MendelianRandomization, TwoSampleMR, and 
MR-Pleiotropy Residual Sum and Outlier test packages in R version 
3.2.22,23 Bonferroni-corrected 2-sided P values (P=0.004; 0.05/12) for 
12 tests (3 exposures and 4 outcomes) were used.
We performed conventional MR analyses for LDLC using variants 
in genes encoding targets for LDLC lowering (HMGCR, PCSK9, and 
NPC1L1) or HDLC elevation (CETP). Variants in these genes were 
previously selected using r2<0.4, and thus we incorporated covari-
ance matrices in all MR analyses.8,24
Odds ratio (OR) thresholds were calculated for all stroke subtypes 
given the case count, sample size, instrument strength, and 80% 
minimum power.25 For ischemic stroke, we had 80% power to detect 
associations with ORs as low as 1.11 with an instrument explaining 
6.4% of the exposure and as high as 1.26 with instruments explaining 
1.2% of the exposure. The OR range was 1.24 to 1.56 for large artery 
atherosclerosis stroke, 1.21 to 1.49 for small artery occlusion stroke, 
and 1.20 to 1.48 for cardioembolic stroke (Table III in the online-only 
Data Supplement).
Results
The associations between LDLC and ischemic stroke and 
subtypes are shown in Figure 1. Genetically predicted LDLC 
was associated with higher risk for ischemic stroke (OR: 1.12; 
95% confidence interval [CI]: 1.01–1.24; per 1-SD elevation 
of LDLC) by conventional MR. MR-Egger showed a stronger 
association (OR: 1.22; 95% CI: 1.05–1.43), and the intercept 
did not indicate pleiotropic bias (P intercept=0.14). In addi-
tion, conventional MR suggested a direct association between 
genetically elevated LDLC and large artery atherosclerosis 
stroke (OR: 1.28; 95% CI: 1.07–1.53). Fully adjusted mul-
tivariable MR and MR-Egger showed stronger associa-
tions (OR: 1.36; 95% CI: 1.17–1.57 and OR: 1.40; 95% CI: 
1.06–1.86, respectively), and MR-Egger intercept showed no 
pleiotropy (P=0.39). After Bonferroni correction, only multi-
variable MR analyses remained significant. Genetically pre-
dicted LDLC did not associate with small artery occlusion nor 
with cardioembolic stroke.
Genetically predicted elevations in HDLC levels were 
associated with lower risk of small artery occlusion stroke 
(OR: 0.79; 95% CI: 0.67–0.93; per 1-SD elevation of HDLC) 
using conventional MR (Figure 2). Similar associations were 
observed using multivariable MR. MR-Egger showed no evi-
dence of pleiotropic bias (P intercept=0.33). Multivariable MR 
analyses showed a weaker evidence of association between 
HDLC and ischemic stroke as it did not pass Bonferroni cor-
rection. In addition, the MR-Egger estimate showed a null 
association (OR: 1.01; 95% CI: 0.87–1.18). No associations 
were observed for HDLC with large artery atherosclerosis or 
cardioembolic strokes. Finally, genetically elevated triglycer-
ides did not associate with ischemic stroke or any of its sub-
types (Figure 3).
In sensitivity analyses, MR-Pleiotropy Residual Sum and 
Outlier test showed outlier pleiotropy between LDLC and isch-
emic stroke. After excluding outlier SNPs, LDLC remained 
associated with ischemic stroke (OR: 1.14; 95% CI: 1.06–1.24; 
P=0.0009; Table IV in the online-only Data Supplement). The 
2-stage Steiger filtering resulted in 66- and 61-SNP LDLC 
Figure 1. Association of low-density lipoprotein cholesterol with ischemic stroke and subtypes using different Mendelian randomization 
(MR) analyses. Odds ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 
2-sample MR that forces the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other 
lipid traits and MR-Egger adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide 
polymorphisms that adjusts for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting 
plasma insulin. CI indicates confidence interval.
 by guest on M
arch 29, 2018
http://stroke.ahajournals.org/
D
ow
nloaded from
 
4  Stroke  April 2018
instruments (explaining 5.9% and 5.6% of LDLC variance, 
respectively) that indicated direct association between LDLC 
and ischemic stroke (P=0.0001). Excluding SNPs associated 
with HDLC and triglycerides resulted in a 55-SNP instru-
ment (explaining 3.6% of LDLC variance), which showed 
direct association with ischemic stroke (OR: 1.20; 95% CI: 
1.08–1.34). All LDLC instruments after Steiger filtering and 
exclusion of HDLC and triglycerides SNPs showed direct 
association with large artery atherosclerosis stroke with ORs 
ranging between 1.32 and 1.36 using conventional MR.
MR-Pleiotropy Residual Sum and Outlier test showed out-
lier pleiotropy between HDLC and small artery atheroscle-
rosis stroke (Table V in the online-only Data Supplement). 
Removal of outlier SNPs did not change our results (OR: 0.81; 
95% CI: 0.70–0.93; P=0.003). Two-stage Steiger filtering 
resulted in 76- and 50-SNP HDLC instruments (explaining 
4.9% and 4.2% of HDLC variance, respectively), which also 
showed nominal associations (P=0.014 and 0.010, respec-
tively). Excluding LDLC- and triglycerides-associated SNPs 
resulted in a 50-SNP instrument (explaining 1.9% of HDLC 
variance) that did not show a significant association (OR: 
0.82; 95% CI: 0.65–1.04; P=0.11).
Finally, an LDLC-lowering instrument created by SNPs in 
the LDLR gene supported a causal role of LDLC in ischemic 
(OR: 0.78; 95% CI: 0.63–0.96; per 1-SD lower LDLC) and 
large artery stroke (OR: 0.66; 95% CI: 0.45–0.98). Although, 
the HMGCR LDLC instrument showed lower risk of isch-
emic stroke (OR: 0.70; 95% CI: 0.50–0.99), no association 
was observed with large artery stroke, but a strong association 
was observed with small artery occlusion stroke (OR: 0.41; 
95% CI: 0.21–0.81). The PCSK9 LDLC instrument showed 
an unexpected higher risk of cardioembolic stroke with 
lower LDLC but no association with all ischemic or the other 
stroke subtypes. The NPC1L1 instrument showed lower risk 
of ischemic (OR: 0.61; 95% CI: 0.37–0.99), large artery ath-
erosclerosis (OR: 0.18; 95% CI: 0.06–0.53), and small artery 
occlusion (OR: 0.22; 95% CI: 0.08–0.56) strokes. Finally, a 
CETP instrument for higher HDLC suggested lower risk of 
ischemic (OR: 0.94; 95% CI: 0.88–1.00) and small artery 
occlusion stroke (OR: 0.88; 95% CI: 0.78–1.00; Figure I in 
the online-only Data Supplement).
Discussion
This MR study provides evidence for a direct relationship 
between LDLC and ischemic stroke that is likely driven by 
an association with large artery atherosclerosis stroke. There 
was no evidence of association of LDLC with small artery 
occlusion or cardioembolic stroke. In addition, results from 
this study provide evidence for an inverse association between 
HDLC and small artery occlusion stroke. Finally, this study 
does not provide any support for association of genetically 
higher triglycerides with ischemic, large artery atherosclero-
sis, small artery occlusion, or cardioembolic strokes.
Observational studies have provided discrepant results con-
cerning the relationship of LDLC, HDLC, and triglycerides 
with ischemic stroke. Most but not all observational studies 
Figure 2. Association of high-density lipoprotein cholesterol with ischemic stroke and subtypes using different Mendelian randomization 
(MR) analyses. Odds ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 
2-sample MR that forces the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other 
lipid traits and MR-Egger adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide 
polymorphisms that adjust for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting 
plasma insulin. CI indicates confidence interval.
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support a direct association between elevated total and LDLC 
and ischemic stroke.1,26,27 In addition, most studies report an 
inverse relationship between HDLC and ischemic stroke27–30 
and a direct relationship between triglycerides and ischemic 
stroke.1,27–31 However, most observational studies have not 
performed subtyping of ischemic stroke into different patho-
physiological stroke subtypes. Few studies have shown direct 
association between total cholesterol and large artery athero-
sclerosis stroke.32 However, the association between LDLC and 
small artery occlusion stroke has not been consistent among 
studies.1,33,34 Randomized controlled trials (RTCs) have provided 
evidence for a causal association between LDLC and ischemic 
stroke while such evidence is lacking for HDLC and triglycer-
ides. Statins have consistently shown benefits in terms of car-
diovascular risk reduction including stroke.2,35 However, there 
is insufficient evidence from HDLC and triglyceride-targeted 
trials concerning if elevation of HDLC or lowering of triglycer-
ides decreases the risk of ischemic stroke. In a meta-analysis of 
clinical trials, none of 3 HDLC raising agents reduced ischemic 
stroke risk in patients treated with statins, which could poten-
tially be related to off-target effects by these drugs.5
Clinical trials have previously shown that statins, and more 
recently PCSK9 inhibitors, provide comparable risk reduction 
in both ischemic stroke and CAD.2,36 Attributable to a lifelong 
genetic exposure to lower LDLC, MR studies have demon-
strated higher risk reduction in CAD compared with RCTs 
(≈70% versus ≈25% per 1 mmol/L lower LDLC).2,6,36 Given 
the comparable effects of LDL lowering drugs in RCTs, one 
would expect MR studies with LDLC to provide a similar 
magnitude of risk increase for ischemic stroke as earlier shown 
for CAD. However, our study indicated only a 12% increased 
risk of ischemic stroke and 28% increased risk of large artery 
atherosclerosis stroke with 1 mmol/L higher LDLC. Although 
the MR-Egger estimates provided larger estimates (22% and 
40%, respectively), they remained below the expected effect 
of lifelong exposure to elevated LDLC. One explanation for 
lower estimates could lie in the pathophysiological heteroge-
neity of ischemic stroke. In addition, it may be partially attrib-
uted to differences in the characteristics of the stroke cases in 
RCTs compared with those in our study or other MR studies. 
It is likely that lipid-lowering RCTs are enriched for lipid-
related cardiovascular disease and that the incident stroke 
cases may carry more of a large artery atherosclerosis pheno-
type, that is, patients with higher risk by LDLC in our study 
compared with any ischemic stroke. Finally, prolonged expo-
sure to elevated LDLC could have different consequences in 
stroke versus CAD.
As discussed above, our results suggest that genetic con-
tribution of LDLC-related mechanisms in large artery stroke 
may be of lower magnitude compared with CAD despite 
sharing an atherosclerotic pathogenic origin. In fact, a recent 
study reported that a PCSK9 loss-of-function variant was 
not associated with ischemic nor large artery atherosclerosis 
stroke.37
 Similarly, no association between lower LDLC by 
the PCSK9 variants and ischemic stroke or large artery ath-
erosclerosis stroke was observed in our study. In addition, our 
Figure 3. Association of triglycerides with ischemic stroke and subtypes using different Mendelian randomization (MR) analyses. Odds 
ratio (OR) of ischemic stroke per 1-SD increase in each lipid trait. Conventional MR estimates were derived from 2-sample MR that forces 
the intercept of the slope line to zero and does not account for pleiotropy. Multivariable MR adjusts for other lipid traits and MR-Egger 
adjusts for unbalanced pleiotropy. *Multivariable MR analysis using summary estimates of 343 single nucleotide polymorphisms that 
adjust for lipid traits, body mass index (BMI), waist hip ratio adjusted for BMI, fasting plasma glucose, and fasting plasma insulin. CI indi-
cates confidence interval.
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study indicated a weaker effect of LDLC lowering through 
HMGCR and NPC1L1 variants on ischemic stroke (OR: 
0.70 and 0.61 per 1 mmol/L lower LDLC) compared with 
previously reported effect by the same instruments on CAD 
(OR: ≈0.50 per 1 mmol/L lower LDLC).8 In line with these 
observations, previous GWAS studies have indicated enrich-
ment of lipid pathways in CAD but not in ischemic stroke 
pathogenesis.37,38
Our study does not provide support for a causal relation-
ship between LDLC and small artery occlusion or cardioem-
bolic stroke. However, it is important to remember that our 
results cannot exclude a weaker causal association. We were 
80% powered to detect a minimum OR of 1.2 for both of these 
outcomes, and lack of evidence in these MR analyses could 
be a consequence of insufficient statistical power. In contrast, 
the lower risk of ischemic stroke by HMGCR-mediated lower 
LDLC in our study appeared to be solely mediated through 
its effect on small artery occlusion. This is in contrast to the 
J-STARS trial that found a lower risk of large artery athero-
sclerosis but not small artery occlusion or cardioembolic 
stroke among individuals in the pravastatin arm of the trial.4 
However, both the HMGCR instrument and the J-STARS trial 
were underpowered to detect associations with stroke sub-
types, and therefore these results should not be taken as con-
clusive evidence. Finally, our study indicated a larger effect 
of NPC1L1-mediated lower LDLC on ischemic, large artery 
atherosclerosis, and small artery occlusion, which is in line 
with reported larger risk reduction of ischemic stroke (21%) 
compared with myocardial infarction (13%) by ezetimibe in 
the IMPROVE-IT trial (Improved Reduction of Outcomes: 
Vytorin Efficacy International Trial).39
The relationship between HDLC and ischemic stroke 
seems to be less clear as compared with LDLC in our 
study. Estimates from conventional and multivariable MR 
indicated nominal evidence for a weak inverse association, 
which vanished in the MR-Egger analysis. However, the 
MR-Egger intercept was not significant, and the MR-Egger 
analysis is less powerful compared with the inverse-vari-
ance–weighted methods.12 A recent Framingham study 
investigated the role of 47 HDLC SNPs in ischemic stroke 
and reported no association. However, that study included 
301 ischemic stroke cases compared with 16 851 in the 
present study.40 Evidence from previous MR studies does 
not support a causal role between HDLC and CAD,6,41 
which is also consistent with our results of no associa-
tion between genetically elevated HDLC and large artery 
atherosclerosis stroke. However, our study suggests an 
inverse association between HDLC and small artery occlu-
sion stroke supported by both conventional and multivari-
able MR analyses but not by the less-powered MR-Egger. 
In addition, CETP-mediated higher HDLC provided some 
evidence for lower risk of small artery occlusion stroke. 
This needs to be further investigated in future MR stud-
ies with larger numbers and MRI-confirmed cases of small 
artery occlusion stroke. The putative role of HDLC in small 
artery occlusion or lacunar strokes has been reported in few 
previous studies. Higher serum HDLC has previously been 
found to associate with higher cerebral vasculature CO2 
reactivity that reflects the function of smaller intracerebral 
arteries.42 There is also some evidence that HDLC may 
affect endothelial dysfunction or brain soluble amyloid 
levels, which are probable pathogenic mechanisms in small 
artery occlusion stroke.43–45
Our study does not support a causal role of triglycerides 
in ischemic stroke. This in contrast to recent MR studies 
that support a direct causal role between triglycerides and 
CAD.6,7,46 Indeed, these results provide further support for 
a differential role of lipids in stroke and CAD, as discussed 
above. Our results are in line with those from clinical trials 
that have not been able to provide evidence that triglyceride 
lowering would affect stroke risk. In addition, our study does 
not show any direct causal relationship between triglycerides 
and large artery atherosclerosis stroke even though it shares 
common pathogenic mechanisms with CAD.
The main advantages of our study include the large num-
ber of ischemic stroke cases and the availability of data on 
ischemic stroke subtypes. In addition, we have used the most 
up-to-date summary-level genetic data on lipids and other 
cardiometabolic traits. Finally, we have used several meth-
ods to correct for a possible pleiotropic bias (multivariable 
MR, MR-Egger, Steiger filtering, and exclusion of pleiotro-
pic SNPs). However, our study still has several limitations. 
Although the number of ischemic stroke cases was rela-
tively large, the numbers of ischemic stroke subtypes were 
still relatively low, and therefore lack of evidence in some 
of our MR analyses could be a consequence of insufficient 
statistical power. However, most estimates were consistent 
using different MR approaches, which indicates that the 
observed associations are not likely to be by chance observa-
tions. Finally, we cannot rule out bias because of population 
stratification. However, all the SNP trait and SNP disease 
estimates were obtained from predominantly studies of 
European ancestry, which indicates that the cases, controls, 
and lipid measurements were obtained from comparable or 
similar populations.
Our results suggest that elevated LDLC levels increase the 
risk for ischemic stroke, indicating that further LDLC reduc-
tion is likely to result in further risk reduction in ischemic 
stroke. Our study further suggests that the LDLC-lowering 
effect may be of particular importance for risk reduction of 
large artery atherosclerosis stroke. However, elevated triglyc-
erides do not increase the risk for ischemic stroke or any of its 
subtypes, indicating that future triglyceride-targeted therapies 
may not lead to beneficial effects in terms of decreasing the 
risk of ischemic stroke although they will likely lead to benefi-
cial coronary effects.46 Finally, our results provide some evi-
dence of lower small artery occlusion stroke risk by elevated 
HDLC, but this needs to be confirmed by adequately powered 
future studies.
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Supplemental Table I. Association of 185 lipid-associated single nucleotide polymorphisms 
with lipid traits in the Global Lipids Genetics Consortium genome-wide association meta-
analysis. 
 
   LDL cholesterol HDL cholesterol Triglycerides 
SNP A1 A2 beta se p beta se p beta se p 
rs10019888 G A 0.018 0.005 3.23E-04 -0.027 0.005 4.90E-08 0.023 0.005 2.28E-06 
rs10029254 T C 0.006 0.004 2.05E-01 -0.009 0.004 4.87E-02 0.027 0.004 7.55E-09 
rs1010167 G C 0.025 0.004 6.22E-11 -0.004 0.004 3.96E-01 0.002 0.004 8.08E-01 
rs10102164 A G 0.032 0.005 3.74E-11 -0.001 0.004 7.97E-01 0.011 0.004 6.87E-03 
rs10282707 C T 0.008 0.004 4.23E-02 0.025 0.004 1.03E-11 -0.009 0.003 6.52E-03 
rs103294 T C 0.007 0.005 1.23E-01 0.052 0.004 4.00E-30 -0.002 0.004 7.52E-01 
rs1035744 T C 0.007 0.004 1.58E-01 -0.006 0.004 1.55E-01 0.021 0.004 1.45E-07 
rs10401969 T C 0.118 0.007 2.65E-54 -0.013 0.007 1.02E-01 0.121 0.007 9.70E-70 
rs10493326 A G 0.021 0.004 1.91E-06 -0.001 0.004 6.73E-01 0.031 0.004 2.00E-15 
rs10513688 A G 0.022 0.006 2.18E-03 -0.005 0.006 6.08E-01 0.031 0.006 1.54E-07 
rs10773105 T C 0.006 0.004 1.22E-01 -0.036 0.004 3.20E-24 0.004 0.003 5.09E-01 
rs10790162 A G 0.076 0.007 1.09E-23 -0.095 0.007 9.91E-40 0.231 0.007 1.10E-249 
rs10832962 T C 0.032 0.004 6.62E-14 0.004 0.004 3.33E-01 0.011 0.004 5.18E-03 
rs10861661 C A 0.000 0.005 9.29E-01 -0.022 0.004 5.05E-07 0.023 0.004 2.60E-07 
rs10903129 G A 0.033 0.004 3.03E-17 0.001 0.003 8.59E-01 0.008 0.003 5.88E-03 
rs11045163 A G 0.006 0.004 1.63E-01 -0.022 0.004 3.20E-09 0.010 0.003 2.85E-03 
rs11220462 A G 0.059 0.006 6.61E-21 -0.016 0.006 8.75E-03 0.019 0.005 1.32E-03 
rs11246602 C T 0.002 0.006 5.26E-01 0.034 0.005 1.68E-10 -0.009 0.005 1.92E-01 
rs11563251 T C 0.035 0.006 4.50E-08 0.006 0.006 3.65E-01 0.008 0.006 8.26E-02 
rs11660468 T C 0.011 0.004 3.41E-03 0.039 0.003 3.60E-27 -0.001 0.003 8.80E-01 
rs1169288 C A 0.038 0.004 6.45E-21 0.010 0.004 9.13E-03 0.003 0.004 4.20E-01 
rs1186380 C T 0.024 0.004 8.46E-08 0.000 0.004 8.69E-01 -0.003 0.004 5.21E-01 
rs12133576 A G 0.010 0.004 3.83E-03 0.024 0.004 6.15E-11 -0.009 0.003 1.19E-02 
rs12145743 T G 0.004 0.004 3.38E-01 -0.020 0.004 1.80E-08 0.012 0.004 5.56E-04 
rs12226802 G A 0.000 0.005 6.19E-01 0.033 0.005 1.29E-09 -0.007 0.005 2.30E-01 
rs1250229 C T 0.024 0.004 3.13E-08 -0.003 0.004 4.04E-01 0.009 0.004 1.39E-02 
rs12525163 T C 0.004 0.004 2.56E-01 -0.022 0.004 1.52E-07 0.009 0.004 3.70E-02 
rs1260326 T C 0.021 0.004 1.51E-07 -0.011 0.004 1.74E-03 0.115 0.003 2.29E-239 
rs12670798 C T 0.034 0.004 4.81E-14 -0.001 0.004 7.33E-01 0.010 0.004 1.68E-02 
rs12678919 A G 0.008 0.006 5.05E-01 -0.155 0.006 1.38E-149 0.170 0.006 1.82E-199 
rs12801636 A G 0.008 0.005 1.45E-01 0.024 0.004 3.15E-08 -0.018 0.004 1.35E-05 
rs13107325 C T 0.016 0.008 5.74E-02 0.071 0.008 1.07E-15 -0.031 0.008 3.98E-05 
rs13326165 G A 0.004 0.005 2.67E-01 -0.029 0.004 9.04E-11 0.021 0.004 2.96E-06 
rs1341267 A C 0.002 0.004 8.87E-01 0.002 0.003 8.59E-01 -0.018 0.003 8.30E-07 
rs1367117 A G 0.119 0.004 9.48E-183 -0.022 0.004 7.59E-09 0.025 0.004 1.06E-11 
rs1482852 A G 0.003 0.004 5.75E-01 -0.021 0.004 6.34E-08 0.013 0.004 3.68E-04 
rs1515110 T G 0.006 0.004 9.36E-02 -0.032 0.004 8.04E-18 0.027 0.003 8.54E-14 
rs1532085 A G 0.003 0.004 6.47E-01 0.107 0.004 1.24E-188 0.031 0.003 2.32E-18 
rs1535 A G 0.053 0.004 7.77E-41 0.039 0.004 5.74E-27 -0.046 0.004 5.49E-40 
rs1564348 C T 0.048 0.005 2.76E-21 -0.008 0.005 1.68E-01 0.016 0.005 4.91E-04 
rs16831243 T C 0.038 0.006 9.06E-12 0.011 0.005 3.90E-02 -0.001 0.005 9.87E-01 
rs1688030 C T 0.016 0.008 3.73E-02 0.009 0.007 2.46E-01 0.038 0.007 1.99E-07 
rs1689797 A C 0.014 0.004 4.92E-04 -0.036 0.004 2.85E-21 0.011 0.004 2.42E-02 
rs16942887 A G 0.001 0.005 7.98E-01 0.083 0.005 8.28E-54 -0.012 0.005 2.96E-02 
rs17145738 T C 0.004 0.006 5.43E-01 0.041 0.005 4.95E-13 -0.115 0.005 9.42E-99 
rs17173637 C T 0.007 0.006 3.81E-01 -0.036 0.006 1.90E-08 0.021 0.006 1.04E-03 
rs17286602 T A 0.003 0.004 4.24E-01 -0.021 0.003 2.93E-07 0.006 0.003 1.62E-01 
rs17345563 A G 0.036 0.006 2.04E-09 -0.014 0.005 4.62E-03 0.015 0.005 3.90E-03 
rs174532 A G 0.035 0.004 3.13E-16 0.021 0.004 6.93E-08 -0.016 0.004 3.44E-05 
rs17508045 T C 0.049 0.007 4.91E-12 -0.009 0.006 4.66E-02 -0.008 0.006 4.00E-01 
rs17695224 G A 0.011 0.004 1.25E-02 0.029 0.004 2.42E-13 -0.012 0.004 1.13E-02 
rs17788930 A G 0.005 0.004 2.18E-01 0.036 0.004 1.53E-22 -0.011 0.004 2.80E-03 
rs17789218 T C 0.024 0.004 3.26E-07 -0.004 0.004 1.35E-01 0.006 0.004 6.65E-02 
rs1781930 G A 0.010 0.005 5.70E-02 0.002 0.005 6.25E-01 0.031 0.004 2.51E-11 
rs1800562 G A 0.062 0.008 8.25E-14 0.007 0.007 2.42E-01 -0.013 0.007 1.72E-01 
rs1800961 C T 0.069 0.011 6.03E-10 0.127 0.010 1.64E-34 0.002 0.009 7.02E-01 
rs181362 C T 0.007 0.005 7.93E-02 0.038 0.004 9.24E-18 0.009 0.004 2.81E-02 
rs1883025 C T 0.030 0.004 6.14E-11 0.070 0.004 1.50E-65 0.022 0.004 2.91E-07 
rs1998013 C T 0.381 0.022 3.02E-48 -0.035 0.020 4.13E-01 -0.009 0.020 6.57E-01 
rs2000999 A G 0.065 0.005 4.22E-41 0.002 0.004 9.52E-01 0.019 0.004 7.49E-07 
rs2030746 T C 0.021 0.004 8.61E-09 -0.003 0.004 3.06E-01 0.003 0.004 4.91E-01 
rs205262 A G 0.009 0.004 3.13E-02 0.028 0.004 3.88E-13 -0.003 0.004 8.03E-01 
rs2068888 G A 0.017 0.004 3.89E-05 -0.019 0.004 2.15E-06 0.024 0.003 1.68E-11 
rs2073547 G A 0.049 0.005 1.92E-21 -0.005 0.005 3.10E-01 0.015 0.004 3.39E-03 
rs217386 G A 0.036 0.004 1.20E-19 -0.001 0.004 4.99E-01 0.010 0.003 6.35E-03 
rs2240327 G A 0.001 0.004 9.71E-01 0.024 0.003 1.11E-11 -0.002 0.003 8.67E-01 
rs2241210 G A 0.008 0.004 8.55E-02 0.033 0.004 2.49E-20 0.003 0.003 2.47E-01 
rs2247056 C T 0.025 0.004 1.42E-08 0.012 0.004 3.79E-03 0.038 0.004 3.86E-21 
rs2255141 A G 0.030 0.004 1.32E-13 0.034 0.004 2.35E-17 -0.021 0.004 1.70E-09 
rs2278236 A G 0.007 0.004 1.27E-01 0.033 0.004 3.19E-18 -0.014 0.003 1.52E-04 
rs2287623 G A 0.022 0.004 5.40E-08 0.011 0.004 2.05E-03 -0.001 0.003 9.20E-01 
rs2288002 G A 0.029 0.004 1.26E-12 0.007 0.004 1.21E-01 0.009 0.003 1.69E-03 
rs2290547 A G 0.001 0.005 7.93E-01 -0.030 0.005 3.69E-09 0.010 0.004 2.21E-02 
rs2293889 T G 0.015 0.004 2.42E-04 -0.031 0.004 4.27E-17 0.006 0.003 1.51E-01 
rs2294261 A C 0.033 0.004 6.57E-17 -0.009 0.004 2.06E-02 0.002 0.003 5.87E-01 
rs2297374 C T 0.033 0.004 1.26E-15 -0.006 0.004 2.18E-01 0.009 0.003 4.74E-03 
rs2303975 G A 0.001 0.005 9.35E-01 -0.028 0.005 1.59E-07 0.012 0.005 2.68E-02 
rs2326077 C T 0.034 0.004 5.00E-17 0.004 0.004 2.18E-01 0.018 0.003 5.35E-07 
rs2328223 C A 0.030 0.005 5.63E-09 0.000 0.005 8.59E-01 -0.007 0.005 1.15E-01 
rs2412710 G A 0.002 0.015 6.40E-01 0.084 0.014 1.36E-09 -0.099 0.013 1.66E-11 
rs2472509 G T 0.000 0.004 7.08E-01 0.023 0.004 1.21E-09 -0.002 0.004 7.22E-01 
rs2587534 A G 0.039 0.004 8.06E-25 0.009 0.003 3.85E-03 0.004 0.003 2.71E-01 
rs2602836 G A 0.001 0.004 8.31E-01 -0.019 0.003 4.96E-08 0.009 0.003 2.12E-02 
rs261342 C G 0.003 0.007 7.36E-01 -0.107 0.006 1.47E-68 -0.045 0.006 2.53E-12 
rs2642438 G A 0.035 0.004 7.32E-16 0.030 0.004 7.78E-14 -0.017 0.004 5.27E-06 
rs2652834 A G 0.002 0.005 7.32E-01 -0.029 0.004 3.59E-11 0.025 0.004 1.92E-08 
rs267733 A G 0.033 0.005 5.29E-09 -0.016 0.005 3.58E-03 0.003 0.005 6.16E-01 
rs2710642 A G 0.024 0.004 6.09E-09 -0.010 0.004 7.69E-03 0.007 0.003 4.71E-02 
rs2737252 G A 0.031 0.004 7.04E-14 0.013 0.004 3.94E-03 0.009 0.004 1.07E-02 
rs2923084 G A 0.012 0.005 1.84E-02 -0.026 0.005 5.02E-08 0.012 0.004 5.97E-03 
rs2925979 C T 0.003 0.004 6.30E-01 0.035 0.004 1.32E-19 -0.021 0.004 2.14E-07 
rs2954022 C A 0.055 0.004 2.39E-47 -0.040 0.003 2.12E-29 0.078 0.003 2.23E-113 
rs2980885 G A 0.031 0.005 6.26E-11 -0.035 0.004 1.73E-14 0.058 0.004 3.00E-40 
rs314253 T C 0.024 0.004 3.44E-10 -0.003 0.004 3.53E-01 0.009 0.003 2.98E-02 
rs3198697 T C 0.010 0.004 6.86E-03 0.016 0.004 3.28E-05 -0.020 0.003 2.21E-08 
rs326214 A G 0.007 0.005 2.04E-01 -0.061 0.005 2.17E-36 0.024 0.004 3.79E-07 
rs355838 T G 0.018 0.004 3.05E-05 -0.019 0.004 4.10E-07 0.014 0.003 1.21E-04 
rs364585 G A 0.025 0.004 4.28E-10 0.001 0.004 8.22E-01 -0.002 0.003 4.40E-01 
rs3741414 C T 0.016 0.004 3.41E-04 -0.030 0.004 6.10E-14 0.028 0.004 1.44E-13 
rs3761445 A G 0.008 0.004 3.99E-02 -0.016 0.004 3.94E-06 0.023 0.003 8.06E-12 
rs3780181 A G 0.045 0.007 1.76E-09 0.004 0.007 5.42E-01 -0.007 0.007 4.91E-01 
rs3817588 T C 0.026 0.005 4.43E-07 -0.005 0.004 2.30E-01 0.067 0.004 1.30E-55 
rs3822072 A G 0.007 0.004 3.71E-02 -0.025 0.003 4.06E-12 0.018 0.003 5.74E-07 
rs38855 A G 0.001 0.004 9.73E-01 -0.015 0.003 9.05E-05 0.019 0.003 2.11E-08 
rs3996352 A G 0.005 0.004 1.21E-01 -0.030 0.003 3.59E-17 0.018 0.003 5.88E-08 
rs4075205 C T 0.012 0.004 8.21E-04 -0.022 0.004 3.54E-09 0.009 0.003 5.16E-02 
rs4148005 G T 0.015 0.004 1.49E-04 -0.028 0.004 5.74E-14 0.007 0.004 4.37E-02 
rs4148218 G A 0.044 0.005 6.76E-21 -0.003 0.004 4.56E-01 0.004 0.004 2.95E-01 
rs4240624 A G 0.067 0.006 2.62E-23 0.082 0.006 1.32E-45 -0.028 0.006 1.09E-06 
rs4332136 C G -0.043 0.098 6.60E-01 0.480 0.065 1.00E-13 0.024 0.053 6.50E-01 
rs442177 T G 0.016 0.004 6.09E-05 -0.022 0.003 2.19E-09 0.031 0.003 1.32E-18 
rs4465830 G A 0.009 0.005 5.99E-02 -0.060 0.004 5.18E-40 0.053 0.004 2.98E-34 
rs4530754 A G 0.028 0.004 3.58E-12 0.001 0.003 9.34E-01 0.002 0.003 7.42E-01 
rs4587594 G A 0.049 0.004 1.63E-32 0.015 0.004 1.08E-04 0.069 0.004 3.50E-82 
rs4650994 A G 0.003 0.004 3.38E-01 -0.021 0.003 6.70E-09 0.002 0.003 3.98E-01 
rs4660293 G A 0.011 0.004 1.23E-02 -0.035 0.004 2.86E-18 0.020 0.004 2.87E-07 
rs4722551 C T 0.039 0.005 3.95E-14 0.010 0.005 2.47E-02 -0.027 0.004 1.58E-09 
rs4791641 C T 0.020 0.004 1.31E-07 0.004 0.003 9.51E-02 -0.003 0.003 4.59E-01 
rs4846914 G A 0.004 0.004 2.34E-01 -0.048 0.003 3.51E-41 0.040 0.003 7.20E-31 
rs4871137 G T 0.004 0.004 2.36E-01 0.021 0.004 1.93E-07 0.001 0.004 6.56E-01 
rs4917014 G T 0.005 0.004 2.46E-01 0.022 0.004 1.03E-08 -0.001 0.004 8.87E-01 
rs4921914 C T 0.023 0.004 1.92E-07 0.002 0.004 3.94E-01 0.035 0.004 4.87E-17 
rs492571 T C 0.003 0.010 4.72E-01 0.066 0.009 1.27E-12 -0.080 0.009 6.74E-17 
rs492602 G A 0.029 0.004 9.42E-14 -0.003 0.004 4.27E-01 0.014 0.004 2.48E-04 
rs4939883 C T 0.021 0.005 1.47E-05 0.080 0.005 1.80E-66 0.005 0.004 3.81E-01 
rs4942486 T C 0.024 0.004 2.26E-11 -0.014 0.003 1.16E-04 0.007 0.003 2.38E-02 
rs4969178 G A 0.011 0.004 8.20E-03 0.026 0.004 1.53E-12 -0.018 0.003 5.70E-06 
rs4976033 A G 0.001 0.004 8.75E-01 0.022 0.004 6.42E-08 -0.014 0.004 2.01E-04 
rs4983559 G A 0.003 0.004 5.83E-01 0.020 0.004 9.57E-09 0.000 0.004 9.71E-01 
rs499974 A C 0.001 0.005 8.26E-01 -0.026 0.004 1.12E-08 -0.009 0.004 5.41E-02 
rs515135 C T 0.139 0.005 1.09E-178 -0.011 0.004 9.01E-03 0.019 0.004 1.36E-04 
rs5763662 T C 0.077 0.012 1.19E-08 0.033 0.011 6.37E-03 0.000 0.011 8.88E-01 
rs579459 C T 0.067 0.005 2.42E-44 0.015 0.004 1.68E-03 -0.014 0.004 1.08E-03 
rs5880 C G 0.047 0.010 1.59E-06 -0.307 0.009 1.37E-233 0.048 0.009 4.71E-08 
rs6016381 T C 0.036 0.004 6.85E-20 -0.008 0.004 6.08E-02 0.014 0.003 1.99E-05 
rs603446 C T 0.009 0.004 1.14E-02 -0.002 0.004 8.73E-01 0.050 0.003 3.92E-43 
rs6065311 C T 0.042 0.004 1.66E-30 0.002 0.003 4.37E-01 0.006 0.003 2.27E-02 
rs634869 T C 0.013 0.004 8.37E-04 -0.023 0.003 1.00E-10 0.027 0.003 1.78E-14 
rs6450176 A G 0.010 0.004 1.18E-02 -0.025 0.004 6.88E-10 0.019 0.004 3.61E-07 
rs646776 T C 0.160 0.004 1.63E-272 -0.034 0.004 2.72E-15 0.003 0.004 3.73E-01 
rs6489818 A G 0.028 0.005 4.57E-09 0.000 0.005 9.28E-01 -0.004 0.004 5.40E-01 
rs6511720 G T 0.221 0.006 3.85E-262 -0.025 0.006 6.32E-05 0.008 0.006 1.04E-01 
rs653178 T C 0.023 0.004 3.88E-09 0.026 0.004 1.06E-12 -0.010 0.003 2.88E-02 
rs6544713 T C 0.081 0.004 4.84E-83 -0.003 0.004 3.88E-01 0.013 0.004 9.60E-04 
rs6603981 T C 0.034 0.004 3.10E-13 0.004 0.004 3.81E-01 0.007 0.004 1.74E-01 
rs6680658 G A 0.006 0.005 2.18E-01 -0.023 0.004 7.49E-08 0.017 0.004 1.44E-05 
rs6805251 T C 0.012 0.004 1.86E-03 0.020 0.004 1.33E-08 -0.001 0.003 9.94E-01 
rs6831256 G A 0.019 0.004 9.07E-07 -0.013 0.004 2.97E-03 0.026 0.004 1.60E-12 
rs6859 A G 0.084 0.004 4.65E-88 -0.018 0.004 7.73E-06 0.014 0.004 8.10E-05 
rs686030 A C 0.009 0.005 2.36E-01 0.055 0.005 4.29E-27 0.025 0.005 2.23E-07 
rs687339 T C 0.011 0.005 9.97E-03 -0.032 0.004 7.11E-13 0.029 0.004 2.51E-12 
rs688 T C 0.054 0.004 1.01E-43 -0.011 0.003 1.55E-03 0.004 0.003 2.18E-01 
rs6882076 C T 0.046 0.004 3.31E-31 0.002 0.004 6.85E-01 0.029 0.004 1.51E-15 
rs702485 G A 0.001 0.004 7.87E-01 0.024 0.003 6.45E-12 -0.002 0.003 4.75E-01 
rs7033354 C T 0.019 0.004 1.42E-06 -0.015 0.004 6.54E-05 0.019 0.003 4.44E-07 
rs7117842 C T 0.019 0.004 7.56E-07 0.027 0.004 1.06E-14 -0.002 0.003 5.43E-01 
rs7225700 C T 0.030 0.004 3.56E-13 0.010 0.004 2.35E-02 -0.005 0.004 2.36E-01 
rs7254892 G A 0.485 0.012 0.00E+00 -0.053 0.011 4.17E-05 -0.124 0.011 1.40E-24 
rs7264396 C T 0.025 0.005 4.41E-08 0.005 0.004 6.02E-02 0.011 0.004 2.58E-03 
rs731839 A G 0.002 0.004 5.17E-01 0.022 0.004 3.44E-09 -0.022 0.004 2.65E-09 
rs7422339 A C 0.008 0.004 1.42E-01 -0.027 0.004 8.73E-10 0.000 0.004 8.60E-01 
rs749671 G A 0.015 0.004 1.05E-04 -0.007 0.004 9.57E-02 0.021 0.003 6.11E-10 
rs7607980 T C 0.007 0.006 2.88E-01 -0.045 0.005 1.81E-15 0.036 0.005 2.41E-12 
rs7640978 C T 0.039 0.007 9.84E-09 0.000 0.006 7.22E-01 0.018 0.006 5.54E-03 
rs7703051 A C 0.073 0.004 1.40E-77 0.002 0.004 4.21E-01 0.006 0.003 1.63E-01 
rs7832643 T G 0.034 0.004 2.67E-17 -0.001 0.004 5.95E-01 0.002 0.003 4.72E-01 
rs7897379 C T 0.010 0.004 4.07E-03 0.019 0.003 1.31E-08 -0.027 0.003 1.27E-17 
rs799160 T C 0.005 0.004 2.86E-01 -0.013 0.004 2.94E-04 0.040 0.004 5.46E-30 
rs8017377 A G 0.030 0.004 2.52E-15 -0.004 0.004 4.34E-01 0.006 0.004 1.42E-01 
rs8077889 C A 0.001 0.005 9.15E-01 -0.021 0.004 1.50E-06 0.025 0.004 9.88E-09 
rs8176720 T C 0.033 0.004 1.59E-17 0.001 0.004 9.43E-01 -0.007 0.004 6.09E-02 
rs838876 G A 0.003 0.004 4.42E-01 -0.049 0.004 7.33E-33 0.005 0.004 3.77E-01 
rs868943 G A 0.026 0.004 8.44E-11 0.008 0.004 3.55E-02 0.014 0.003 3.18E-04 
rs894210 G A 0.007 0.004 1.22E-01 -0.069 0.003 1.68E-84 0.067 0.003 2.94E-89 
rs903319 C T 0.027 0.004 5.22E-11 0.010 0.004 1.22E-02 -0.005 0.004 1.38E-01 
rs931992 T G 0.002 0.006 7.03E-01 0.029 0.005 4.20E-07 -0.009 0.005 1.33E-01 
rs9491696 G C 0.006 0.004 2.64E-01 -0.020 0.003 5.21E-10 0.018 0.003 4.87E-07 
rs952044 C T 0.003 0.004 5.79E-01 0.023 0.004 1.19E-08 -0.010 0.004 2.45E-03 
rs9686661 T C 0.018 0.005 5.29E-04 -0.028 0.004 1.37E-08 0.038 0.004 2.54E-16 
rs9693857 C T 0.005 0.004 2.98E-01 0.004 0.004 5.27E-01 -0.020 0.003 1.69E-08 
rs970548 C A 0.016 0.004 6.65E-04 0.026 0.004 1.71E-10 0.003 0.004 4.59E-01 
rs9875338 G A 0.027 0.004 2.21E-11 0.007 0.004 2.10E-02 0.014 0.003 1.62E-05 
rs9930333 T G 0.000 0.004 7.18E-01 0.020 0.004 2.07E-08 -0.021 0.004 3.25E-08 
rs998584 A C 0.001 0.004 9.36E-01 -0.026 0.004 2.27E-11 0.029 0.004 3.42E-15 
rs9989419 A G 0.028 0.004 2.49E-12 -0.147 0.004 0.00E+00 0.024 0.004 1.05E-11 
 
Reference: Global Lipids Genetics Consortium1 
  
Supplemental Table II. Association of 185 lipid-associated single nucleotide polymorphisms 
with ischemic stroke subtypes in the Stroke Genetics Network genome-wide association meta-
analysis. 
 
   Ischemic Stroke Large Artery Atherosclerosis Small Artery Occlusion Cardio-embolic 
SNP A1 A2 beta se p beta se p beta se p beta se p 
rs10019888 G A 0.007 0.020 0.735 -0.002 0.044 0.962 0.032 0.038 0.398 -0.003 0.037 0.942 
rs10029254 T C 0.001 0.019 0.972 -0.007 0.040 0.857 -0.015 0.037 0.689 -0.002 0.034 0.950 
rs1010167 G C 0.026 0.016 0.095 0.001 0.034 0.981 -0.026 0.030 0.381 0.024 0.029 0.405 
rs10102164 A G 0.035 0.019 0.069 0.040 0.042 0.343 -0.002 0.037 0.964 0.010 0.036 0.773 
rs10282707 C T -0.016 0.015 0.294 0.037 0.034 0.268 -0.017 0.030 0.554 -0.033 0.028 0.243 
rs103294 T C 0.023 0.019 0.237 0.010 0.042 0.819 0.026 0.037 0.474 0.036 0.035 0.304 
rs1035744 T C 0.013 0.017 0.417 -0.025 0.037 0.503 0.000 0.032 0.992 0.012 0.031 0.695 
rs10401969 T C 0.013 0.026 0.613 -0.053 0.060 0.376 -0.024 0.050 0.631 0.067 0.052 0.197 
rs10493326 A G -0.017 0.018 0.348 -0.023 0.038 0.550 -0.056 0.035 0.113 -0.004 0.032 0.899 
rs10513688 A G 0.005 0.024 0.833 0.014 0.053 0.787 -0.008 0.046 0.870 0.091 0.043 0.034 
rs10773105 T C 0.014 0.016 0.372 0.028 0.035 0.423 0.025 0.031 0.409 -0.009 0.029 0.751 
rs10790162 A G -0.006 0.030 0.836 -0.005 0.066 0.943 0.042 0.056 0.449 0.060 0.054 0.266 
rs10832962 T C -0.017 0.017 0.323 -0.028 0.037 0.449 -0.008 0.033 0.800 -0.013 0.031 0.673 
rs10861661 C A 0.000 0.017 0.981 0.021 0.039 0.594 0.019 0.033 0.581 0.008 0.033 0.817 
rs10903129 G A -0.021 0.015 0.160 -0.007 0.033 0.831 -0.019 0.029 0.511 -0.076 0.028 0.006 
rs11045163 A G 0.001 0.015 0.925 0.007 0.034 0.826 -0.005 0.029 0.867 -0.005 0.028 0.854 
rs11220462 A G -0.038 0.023 0.092 0.050 0.048 0.298 -0.050 0.045 0.264 -0.122 0.043 0.004 
rs11246602 C T 0.040 0.024 0.095 -0.016 0.052 0.762 0.008 0.047 0.861 0.060 0.044 0.172 
rs11563251 T C 0.021 0.023 0.355 0.099 0.050 0.049 -0.035 0.044 0.424 -0.020 0.044 0.645 
rs11660468 T C 0.017 0.016 0.288 0.089 0.033 0.008 0.042 0.030 0.165 -0.036 0.028 0.205 
rs1169288 C A 0.027 0.017 0.103 -0.015 0.036 0.684 0.082 0.032 0.009 0.033 0.030 0.272 
rs1186380 C T 0.011 0.018 0.536 0.019 0.039 0.621 -0.004 0.036 0.922 0.031 0.032 0.335 
rs12133576 A G -0.028 0.016 0.074 -0.058 0.035 0.094 -0.045 0.030 0.141 -0.009 0.029 0.760 
rs12145743 T G 0.000 0.016 0.994 0.003 0.035 0.925 0.040 0.032 0.213 0.019 0.030 0.529 
rs12226802 G A 0.044 0.024 0.068 -0.008 0.053 0.875 0.031 0.047 0.503 0.050 0.044 0.257 
rs1250229 C T -0.026 0.018 0.139 -0.020 0.038 0.602 -0.040 0.035 0.257 -0.022 0.032 0.490 
rs12525163 T C 0.008 0.017 0.627 -0.016 0.037 0.666 -0.008 0.032 0.809 -0.013 0.031 0.668 
rs1260326 T C 0.011 0.016 0.484 0.007 0.034 0.826 0.014 0.030 0.647 -0.009 0.028 0.764 
rs12670798 C T -0.013 0.018 0.458 -0.006 0.039 0.887 -0.002 0.033 0.954 -0.003 0.033 0.934 
rs12678919 A G -0.014 0.025 0.573 -0.063 0.053 0.233 0.058 0.048 0.227 -0.029 0.045 0.517 
rs12801636 A G -0.024 0.018 0.182 -0.131 0.040 0.001 -0.003 0.033 0.936 0.010 0.033 0.764 
rs13107325 C T -0.013 0.030 0.665 -0.016 0.064 0.798 -0.013 0.059 0.819 -0.024 0.053 0.647 
rs13326165 G A -0.008 0.019 0.657 -0.062 0.041 0.126 -0.007 0.036 0.849 0.007 0.035 0.851 
rs1341267 A C 0.008 0.016 0.639 0.030 0.035 0.381 0.008 0.033 0.806 0.029 0.029 0.321 
rs1367117 A G -0.007 0.017 0.680 0.022 0.036 0.551 -0.032 0.033 0.330 -0.019 0.031 0.542 
rs1482852 A G 0.008 0.015 0.588 0.021 0.034 0.533 0.022 0.029 0.458 -0.019 0.028 0.513 
rs1515110 T G 0.017 0.016 0.284 0.040 0.034 0.248 0.044 0.030 0.146 0.023 0.029 0.422 
rs1532085 A G -0.003 0.015 0.852 0.077 0.034 0.021 0.003 0.029 0.919 -0.029 0.028 0.308 
rs1535 A G 0.022 0.016 0.184 0.102 0.036 0.005 -0.019 0.031 0.550 0.011 0.030 0.706 
rs1564348 C T -0.013 0.021 0.524 0.084 0.044 0.060 -0.019 0.040 0.638 0.004 0.039 0.921 
rs16831243 T C -0.024 0.024 0.316 -0.031 0.053 0.554 -0.039 0.045 0.382 -0.053 0.044 0.229 
rs1688030 C T 0.027 0.028 0.341 0.000 0.064 0.998 0.071 0.054 0.186 0.006 0.054 0.916 
rs1689797 A C -0.013 0.016 0.424 0.020 0.035 0.556 -0.004 0.031 0.885 0.010 0.029 0.727 
rs16942887 A G -0.012 0.022 0.590 0.065 0.047 0.168 -0.003 0.041 0.946 -0.061 0.041 0.138 
rs17145738 T C -0.043 0.024 0.074 -0.009 0.052 0.866 -0.001 0.047 0.980 -0.017 0.045 0.711 
rs17173637 C T -0.001 0.026 0.965 -0.029 0.058 0.617 0.007 0.052 0.887 0.017 0.048 0.715 
rs17286602 T A 0.020 0.015 0.192 0.049 0.033 0.140 0.010 0.029 0.748 0.010 0.028 0.722 
rs17345563 A G -0.006 0.024 0.804 -0.044 0.052 0.401 -0.019 0.048 0.694 -0.060 0.044 0.174 
rs174532 A G 0.006 0.017 0.732 0.041 0.037 0.261 0.013 0.034 0.700 -0.009 0.031 0.763 
rs17508045 T C 0.045 0.029 0.116 0.070 0.062 0.263 0.050 0.057 0.385 0.074 0.053 0.157 
rs17695224 G A -0.025 0.017 0.146 -0.056 0.037 0.131 -0.012 0.033 0.707 -0.031 0.031 0.326 
rs17788930 A G -0.008 0.016 0.639 0.022 0.035 0.527 -0.064 0.031 0.039 -0.017 0.030 0.573 
rs17789218 T C -0.002 0.019 0.928 -0.062 0.041 0.124 0.005 0.037 0.895 -0.051 0.034 0.134 
rs1781930 G A -0.015 0.021 0.480 0.009 0.045 0.843 0.004 0.041 0.921 -0.029 0.038 0.452 
rs1800562 G A 0.001 0.035 0.971 0.122 0.077 0.111 0.010 0.071 0.885 -0.117 0.061 0.054 
rs1800961 C T -0.027 0.046 0.553 0.008 0.101 0.936 0.029 0.089 0.747 -0.151 0.082 0.066 
rs181362 C T -0.025 0.018 0.165 -0.067 0.040 0.098 -0.038 0.034 0.256 -0.034 0.034 0.314 
rs1883025 C T 0.000 0.017 0.992 -0.021 0.037 0.572 -0.048 0.032 0.133 -0.035 0.031 0.268 
rs1998013 C T NA NA NA NA NA NA NA NA NA NA NA NA 
rs2000999 A G 0.027 0.019 0.156 -0.017 0.042 0.692 -0.031 0.038 0.412 0.029 0.035 0.404 
rs2030746 T C 0.020 0.015 0.194 0.008 0.033 0.811 0.037 0.029 0.208 0.008 0.028 0.787 
rs205262 A G -0.020 0.016 0.223 -0.072 0.036 0.048 -0.010 0.032 0.755 -0.018 0.030 0.548 
rs2068888 G A 0.027 0.015 0.076 0.038 0.033 0.250 -0.016 0.029 0.572 0.050 0.028 0.076 
rs2073547 G A 0.014 0.019 0.459 0.069 0.041 0.094 0.083 0.035 0.018 -0.045 0.036 0.207 
rs217386 G A 0.023 0.016 0.137 0.062 0.034 0.071 0.052 0.031 0.089 -0.025 0.028 0.381 
rs2240327 G A -0.011 0.015 0.463 -0.020 0.033 0.545 -0.018 0.029 0.527 0.018 0.028 0.510 
rs2241210 G A 0.010 0.015 0.492 0.035 0.033 0.288 -0.006 0.029 0.845 0.000 0.028 0.998 
rs2247056 C T 0.011 0.018 0.558 0.032 0.039 0.410 -0.004 0.035 0.917 0.014 0.033 0.666 
rs2255141 A G 0.016 0.017 0.341 0.000 0.037 0.999 0.043 0.033 0.188 0.011 0.031 0.730 
rs2278236 A G -0.004 0.015 0.768 -0.005 0.033 0.890 -0.012 0.029 0.664 0.033 0.027 0.235 
rs2287623 G A 0.017 0.015 0.253 0.039 0.033 0.246 -0.012 0.029 0.671 0.065 0.028 0.021 
rs2288002 G A 0.021 0.015 0.170 0.053 0.033 0.110 -0.005 0.029 0.865 0.022 0.028 0.432 
rs2290547 A G 0.035 0.021 0.095 0.013 0.045 0.782 0.023 0.041 0.573 0.074 0.038 0.049 
rs2293889 T G -0.018 0.016 0.241 -0.038 0.034 0.268 -0.033 0.031 0.277 -0.008 0.028 0.792 
rs2294261 A C -0.005 0.015 0.727 -0.012 0.033 0.712 -0.006 0.030 0.835 -0.021 0.028 0.465 
rs2297374 C T -0.014 0.015 0.354 0.022 0.034 0.507 -0.023 0.029 0.437 -0.012 0.028 0.671 
rs2303975 G A 0.012 0.023 0.598 -0.006 0.051 0.910 0.058 0.045 0.195 -0.023 0.043 0.595 
rs2326077 C T 0.003 0.016 0.830 -0.103 0.035 0.003 0.003 0.031 0.925 -0.010 0.029 0.738 
rs2328223 C A 0.011 0.019 0.551 0.020 0.042 0.638 0.014 0.037 0.701 0.069 0.035 0.046 
rs2412710 G A -0.006 0.045 0.889 -0.069 0.102 0.496 -0.037 0.083 0.660 -0.018 0.085 0.836 
rs2472509 G T 0.000 0.016 0.979 -0.012 0.036 0.739 0.014 0.031 0.650 0.030 0.030 0.313 
rs2587534 A G 0.006 0.015 0.699 0.003 0.034 0.930 0.004 0.030 0.891 -0.003 0.028 0.925 
rs2602836 G A 0.006 0.015 0.711 -0.057 0.033 0.085 0.061 0.029 0.037 -0.024 0.028 0.386 
rs261342 C G 0.020 0.018 0.258 0.068 0.040 0.093 0.022 0.034 0.509 -0.015 0.033 0.646 
rs2642438 G A -0.017 0.017 0.331 -0.032 0.037 0.398 -0.050 0.034 0.139 -0.028 0.031 0.371 
rs2652834 A G 0.013 0.018 0.476 0.062 0.040 0.120 0.009 0.035 0.797 0.026 0.034 0.443 
rs267733 A G 0.005 0.022 0.801 -0.085 0.045 0.060 0.100 0.044 0.022 0.025 0.040 0.522 
rs2710642 A G 0.013 0.016 0.432 -0.011 0.035 0.755 0.006 0.031 0.843 0.068 0.030 0.021 
rs2737252 G A 0.019 0.017 0.260 0.047 0.038 0.213 -0.013 0.033 0.705 0.036 0.032 0.255 
rs2923084 G A 0.019 0.019 0.299 0.075 0.041 0.068 0.011 0.035 0.742 0.026 0.035 0.466 
rs2925979 C T -0.024 0.016 0.136 -0.056 0.036 0.119 -0.019 0.032 0.548 -0.010 0.030 0.741 
rs2954022 C A 0.003 0.015 0.860 0.015 0.033 0.652 -0.003 0.029 0.909 0.008 0.028 0.765 
rs2980885 G A -0.003 0.018 0.849 0.017 0.040 0.670 -0.016 0.035 0.655 0.002 0.033 0.960 
rs314253 T C -0.005 0.016 0.778 0.018 0.035 0.616 0.008 0.031 0.807 -0.050 0.030 0.093 
rs3198697 T C 0.001 0.016 0.930 -0.020 0.034 0.563 0.031 0.031 0.318 0.062 0.029 0.030 
rs326214 A G -0.014 0.016 0.397 0.010 0.036 0.786 -0.029 0.031 0.347 -0.058 0.030 0.054 
rs355838 T G 0.005 0.016 0.779 0.084 0.034 0.013 0.034 0.031 0.270 -0.010 0.029 0.741 
rs364585 G A -0.008 0.016 0.625 -0.040 0.034 0.243 0.014 0.031 0.642 -0.015 0.029 0.604 
rs3741414 C T -0.028 0.019 0.138 -0.040 0.041 0.321 0.004 0.039 0.910 -0.039 0.034 0.255 
rs3761445 A G 0.025 0.016 0.112 0.018 0.034 0.591 0.028 0.031 0.368 -0.025 0.028 0.381 
rs3780181 A G 0.041 0.027 0.138 0.061 0.063 0.340 0.039 0.050 0.440 -0.005 0.053 0.928 
rs3817588 T C -0.010 0.020 0.642 -0.013 0.044 0.761 -0.032 0.040 0.420 0.005 0.037 0.888 
rs3822072 A G 0.027 0.015 0.070 0.110 0.033 0.001 -0.007 0.029 0.813 0.021 0.028 0.453 
rs38855 A G -0.007 0.015 0.657 -0.034 0.033 0.301 0.002 0.029 0.960 -0.055 0.028 0.051 
rs3996352 A G -0.009 0.015 0.551 -0.019 0.033 0.571 0.015 0.029 0.609 -0.007 0.028 0.810 
rs4075205 C T -0.016 0.015 0.298 -0.058 0.033 0.082 -0.024 0.029 0.408 -0.022 0.028 0.432 
rs4148005 G T 0.006 0.016 0.690 0.002 0.035 0.957 -0.019 0.031 0.542 -0.037 0.030 0.216 
rs4148218 G A 0.014 0.019 0.449 -0.013 0.042 0.759 -0.026 0.035 0.456 0.028 0.035 0.432 
rs4240624 A G -0.073 0.025 0.003 -0.063 0.057 0.269 -0.069 0.046 0.135 -0.101 0.048 0.035 
rs4332136 C G 0.062 0.075 0.404 0.374 0.218 0.087 -0.072 0.106 0.496 0.347 0.212 0.102 
rs442177 T G -0.018 0.015 0.233 -0.029 0.033 0.384 -0.073 0.029 0.013 0.060 0.028 0.032 
rs4465830 G A -0.013 0.020 0.506 -0.022 0.043 0.615 0.029 0.039 0.459 -0.009 0.036 0.811 
rs4530754 A G -0.020 0.015 0.188 -0.044 0.033 0.190 -0.071 0.029 0.016 -0.007 0.028 0.801 
rs4587594 G A -0.024 0.016 0.130 -0.072 0.034 0.038 -0.034 0.030 0.255 -0.029 0.029 0.328 
rs4650994 A G -0.019 0.015 0.204 -0.014 0.033 0.663 -0.006 0.029 0.828 -0.040 0.028 0.150 
rs4660293 G A 0.023 0.019 0.224 -0.009 0.040 0.823 0.039 0.038 0.307 0.054 0.033 0.106 
rs4722551 C T 0.056 0.022 0.009 0.039 0.047 0.402 0.081 0.041 0.050 -0.006 0.040 0.880 
rs4791641 C T -0.003 0.015 0.860 -0.057 0.033 0.089 -0.025 0.030 0.399 -0.016 0.028 0.564 
rs4846914 G A -0.018 0.016 0.265 0.045 0.034 0.186 -0.031 0.031 0.318 -0.005 0.029 0.874 
rs4871137 G T 0.002 0.016 0.915 -0.020 0.035 0.568 0.039 0.031 0.202 0.016 0.029 0.597 
rs4917014 G T -0.040 0.016 0.014 -0.023 0.036 0.519 -0.059 0.032 0.064 -0.057 0.030 0.058 
rs4921914 C T 0.013 0.017 0.470 0.019 0.039 0.631 0.029 0.033 0.376 0.013 0.033 0.701 
rs492571 T C -0.019 0.031 0.548 0.010 0.074 0.893 -0.065 0.058 0.264 -0.006 0.060 0.923 
rs492602 G A 0.004 0.015 0.787 0.032 0.033 0.330 0.003 0.029 0.916 -0.010 0.028 0.733 
rs4939883 C T -0.016 0.019 0.392 0.018 0.043 0.676 -0.047 0.037 0.198 -0.022 0.036 0.543 
rs4942486 T C -0.022 0.015 0.130 -0.061 0.033 0.064 -0.010 0.029 0.738 -0.074 0.028 0.007 
rs4969178 G A -0.012 0.015 0.442 -0.028 0.034 0.400 -0.001 0.030 0.987 0.011 0.028 0.711 
rs4976033 A G -0.003 0.016 0.840 -0.026 0.034 0.445 0.021 0.030 0.495 0.025 0.029 0.385 
rs4983559 G A 0.008 0.017 0.639 -0.011 0.037 0.770 0.045 0.031 0.151 -0.036 0.031 0.238 
rs499974 A C 0.041 0.019 0.035 0.082 0.042 0.051 0.120 0.036 0.001 -0.026 0.036 0.478 
rs515135 C T 0.041 0.019 0.031 -0.024 0.042 0.573 0.080 0.038 0.036 0.059 0.036 0.100 
rs5763662 T C -0.034 0.054 0.528 -0.006 0.116 0.961 0.029 0.112 0.796 0.148 0.092 0.107 
rs579459 C T 0.052 0.018 0.004 0.053 0.039 0.183 0.031 0.036 0.390 0.093 0.033 0.005 
rs5880 C G 0.071 0.037 0.054 0.116 0.080 0.147 0.074 0.070 0.293 0.038 0.069 0.579 
rs6016381 T C -0.025 0.016 0.108 0.039 0.035 0.270 -0.025 0.031 0.424 -0.070 0.029 0.015 
rs603446 C T -0.021 0.016 0.186 0.028 0.034 0.407 -0.026 0.030 0.384 -0.032 0.028 0.265 
rs6065311 C T 0.031 0.015 0.040 0.087 0.033 0.008 0.023 0.029 0.435 0.005 0.028 0.847 
rs634869 T C 0.015 0.015 0.311 0.086 0.034 0.010 0.018 0.029 0.548 0.007 0.028 0.812 
rs6450176 A G 0.007 0.017 0.684 0.013 0.037 0.730 0.023 0.032 0.486 -0.018 0.032 0.582 
rs646776 T C 0.025 0.018 0.150 0.070 0.039 0.072 0.022 0.034 0.507 0.016 0.033 0.624 
rs6489818 A G -0.076 0.019 0.000 -0.070 0.044 0.110 -0.115 0.036 0.002 -0.055 0.036 0.124 
rs6511720 G T 0.044 0.024 0.065 0.094 0.053 0.078 0.007 0.045 0.883 0.045 0.044 0.301 
rs653178 T C -0.104 0.016 0.000 -0.109 0.034 0.001 -0.159 0.031 0.000 -0.062 0.029 0.030 
rs6544713 T C 0.010 0.017 0.560 0.041 0.037 0.271 -0.010 0.034 0.766 -0.033 0.031 0.294 
rs6603981 T C -0.006 0.019 0.763 0.007 0.041 0.864 0.014 0.038 0.717 -0.018 0.035 0.606 
rs6680658 G A -0.009 0.018 0.605 0.027 0.040 0.496 -0.003 0.035 0.944 -0.046 0.033 0.155 
rs6805251 T C -0.016 0.016 0.326 -0.010 0.035 0.777 0.038 0.033 0.251 -0.051 0.029 0.084 
rs6831256 G A -0.003 0.015 0.840 0.012 0.033 0.715 0.000 0.029 0.999 -0.024 0.028 0.384 
rs6859 A G 0.005 0.015 0.732 0.060 0.034 0.075 0.021 0.030 0.469 -0.021 0.028 0.452 
rs686030 A C 0.018 0.022 0.417 -0.042 0.046 0.359 0.022 0.043 0.607 0.038 0.040 0.333 
rs687339 T C -0.020 0.018 0.256 -0.068 0.038 0.077 -0.012 0.034 0.734 -0.009 0.033 0.772 
rs688 T C 0.033 0.016 0.034 0.043 0.034 0.201 0.091 0.030 0.002 0.009 0.028 0.759 
rs6882076 C T 0.001 0.016 0.930 0.041 0.034 0.233 0.019 0.030 0.524 -0.002 0.029 0.950 
rs702485 G A -0.004 0.015 0.790 0.002 0.033 0.959 0.012 0.030 0.685 0.005 0.028 0.868 
rs7033354 C T 0.014 0.016 0.373 -0.003 0.035 0.929 -0.019 0.030 0.530 0.092 0.029 0.001 
rs7117842 C T 0.016 0.016 0.293 0.027 0.034 0.429 0.026 0.030 0.382 -0.001 0.029 0.978 
rs7225700 C T 0.029 0.016 0.060 0.028 0.034 0.420 0.038 0.030 0.209 0.018 0.029 0.526 
rs7254892 G A 0.067 0.038 0.075 0.102 0.090 0.255 0.050 0.073 0.489 -0.029 0.070 0.684 
rs7264396 C T -0.017 0.017 0.329 0.035 0.039 0.372 -0.013 0.033 0.688 -0.045 0.032 0.162 
rs731839 A G -0.027 0.016 0.090 -0.092 0.034 0.007 -0.040 0.030 0.184 -0.028 0.029 0.346 
rs7422339 A C NA NA NA NA NA NA NA NA NA NA NA NA 
rs749671 G A 0.007 0.016 0.648 0.031 0.035 0.374 -0.032 0.031 0.292 -0.034 0.029 0.246 
rs7607980 T C -0.020 0.022 0.366 0.017 0.049 0.729 -0.028 0.042 0.499 -0.029 0.040 0.465 
rs7640978 C T 0.018 0.024 0.451 -0.077 0.055 0.159 -0.021 0.045 0.647 0.058 0.047 0.215 
rs7703051 A C 0.016 0.015 0.294 -0.014 0.034 0.686 0.063 0.029 0.031 0.029 0.028 0.307 
rs7832643 T G 0.009 0.015 0.577 0.054 0.034 0.110 -0.023 0.030 0.438 0.018 0.028 0.535 
rs7897379 C T 0.007 0.015 0.657 0.046 0.033 0.162 -0.067 0.029 0.021 0.045 0.027 0.097 
rs799160 T C 0.023 0.015 0.126 0.033 0.033 0.317 0.002 0.029 0.952 0.053 0.028 0.058 
rs8017377 A G -0.007 0.015 0.635 0.011 0.033 0.731 0.024 0.030 0.421 -0.063 0.028 0.024 
rs8077889 C A -0.013 0.018 0.488 0.033 0.040 0.402 0.021 0.035 0.544 0.011 0.033 0.733 
rs8176720 T C 0.018 0.016 0.258 -0.019 0.034 0.574 -0.009 0.030 0.752 0.084 0.029 0.004 
rs838876 G A 0.002 0.016 0.881 -0.020 0.035 0.577 0.001 0.031 0.987 0.031 0.030 0.297 
rs868943 G A 0.007 0.015 0.654 -0.030 0.033 0.361 0.007 0.029 0.811 -0.006 0.028 0.836 
rs894210 G A -0.007 0.016 0.639 -0.010 0.034 0.762 0.000 0.030 0.993 -0.020 0.028 0.473 
rs903319 C T -0.043 0.018 0.015 -0.005 0.038 0.901 0.003 0.035 0.934 -0.079 0.033 0.017 
rs931992 T G -0.023 0.016 0.144 -0.030 0.035 0.386 -0.031 0.031 0.317 -0.030 0.029 0.295 
rs9491696 G C 0.015 0.015 0.312 0.061 0.033 0.062 -0.031 0.029 0.278 0.035 0.027 0.203 
rs952044 C T -0.023 0.016 0.140 -0.032 0.035 0.355 -0.059 0.030 0.049 -0.008 0.029 0.785 
rs9686661 T C 0.030 0.019 0.114 0.013 0.042 0.765 -0.001 0.036 0.986 0.036 0.035 0.309 
rs9693857 C T 0.002 0.015 0.897 -0.003 0.033 0.936 0.033 0.029 0.260 -0.025 0.028 0.371 
rs970548 C A 0.002 0.017 0.904 0.018 0.038 0.633 -0.052 0.034 0.119 0.044 0.032 0.169 
rs9875338 G A 0.001 0.015 0.951 0.007 0.034 0.826 -0.003 0.029 0.910 -0.004 0.028 0.874 
rs9930333 T G -0.011 0.015 0.464 -0.056 0.033 0.091 0.017 0.029 0.559 -0.007 0.028 0.805 
rs998584 A C 0.014 0.016 0.372 0.011 0.035 0.747 0.074 0.032 0.021 -0.005 0.029 0.874 
rs9989419 A G 0.002 0.016 0.892 0.004 0.035 0.912 0.034 0.031 0.277 0.019 0.029 0.506 
 
Reference: NINDS Stroke Genetics Network2
Supplemental Table III. Odds ratios thresholds of ischemic stroke and subtypes at 80% power. 
 
   Odds Ratio at 80% Power 
Instrument N SNPs Variance explained  IS LAA SAO CE 
   positive negative positive negative positive negative positive negative 
LDL cholesterol           
GWAS threshold* 75 6.4 1.109 0.902 1.236 0.809 1.210 0.826 1.203 0.831 
Steiger filter 1† 67 5.9 1.114 0.898 1.246 0.803 1.217 0.822 1.210 0.826 
Steiger filter 2‡ 61 5.6 1.117 0.895 1.253 0.798 1.225 0.816 1.216 0.822 
GWAS restricted§ 56 3.6 1.148 0.871 1.316 0.760 1.280 0.781 1.270 0.787 
           
HDL cholesterol           
GWAS threshold 85 5.9 1.114 0.898 1.246 0.803 1.217 0.822 1.210 0.826 
Steiger filter 1 77 5.0 1.124 0.890 1.268 0.789 1.237 0.808 1.230 0.813 
Steiger filter 2 50 4.2 1.136 0.880 1.292 0.774 1.258 0.795 1.250 0.800 
GWAS restricted 50 1.9 1.205 0.830 1.440 0.694 1.390 0.719 1.375 0.727 
           
Triglycerides           
GWAS threshold 51 4.6 1.129 0.886 1.279 0.782 1.248 0.801 1.240 0.806 
Steiger filter 1 39 4.0 1.139 0.878 1.300 0.769 1.265 0.791 1.255 0.797 
Steiger filter 2 21 3.2 1.156 0.865 1.338 0.747 1.298 0.770 1.290 0.775 
GWAS restricted 16 1.2 1.262 0.792 1.555 0.643 1.490 0.671 1.475 0.678 
* Includes all SNPs that associates with a trait and have a p < 5  10-8  
† Includes all SNPs with r2 values with their traits higher than the other 2 traits 
‡ Includes all SNPs with r2 values with their traits higher and the difference is significant (p<0.05) compared to each of the other 2 traits 
§Includes that associates with a trait and have a p < 5  10-8 and don’t associate with any of the other 2 traits p > 5  10-8 
GWAS, Genome-Wide Association Study; IS, Ischemic Stroke; SAO, Small Artery Occlusion Stroke; CE, Cardio-Embolic Stroke 
 
 
 
 
 
Supplemental Table IV. Sensitivity Mendelian Randomization Analyses of LDL cholesterol with Ischemic Stroke and Subtypes 
 
            95% CI     
Trait Instrument N Variance Method OR lower limit upper limit p p-intercept 
IS GWAS threshold* 75 6.4 Conventional MR 1.122 1.015 1.240 0.0245  
    MR-Egger 1.224 1.050 1.427 0.0098 0.143 
 GWAS threshold (MRPRESSO) 73 6.4 Conventional MR 1.143 1.056 1.237 0.0009  
    MR-Egger 1.179 1.043 1.333 0.0085 0.519 
  Steiger filter 1† 67 5.9 Conventional MR 1.164 1.067 1.269 0.0006  
    MR-Egger 1.207 1.059 1.376 0.0048 0.466 
 Steiger filter 1 (MRPRESSO) 66 5.9 Conventional MR 1.173 1.084 1.270 0.0001  
    MR-Egger 1.195 1.060 1.347 0.0036 0.693 
 Steiger filter 2‡ 61 5.6 Conventional MR 1.158 1.061 1.265 0.0010  
    MR-Egger 1.206 1.058 1.375 0.0050 0.412 
 Steiger filter 2 (MRPRESSO) 60 5.6 Conventional MR 1.168 1.079 1.264 0.0001  
    MR-Egger 1.193 1.059 1.343 0.0036 0.638 
 GWAS restricted§ 56 3.6 Conventional MR 1.186 1.053 1.337 0.0050  
    MR-Egger 1.363 1.098 1.693 0.0051 0.134 
 GWAS restricted (MRPRESSO) 55 3.6 Conventional MR 1.204 1.081 1.340 0.0007  
    MR-Egger 1.335 1.097 1.625 0.0039 0.218 
LAA GWAS threshold 75 6.4 Conventional MR 1.277 1.068 1.527 0.0070   
    MR-Egger 1.405 1.060 1.862 0.0180 0.393 
  Steiger filter 1 67 5.9 Conventional MR 1.360 1.134 1.631 0.0010  
    MR-Egger 1.452 1.098 1.920 0.009 0.544 
 Steiger filter 2 61 5.6 Conventional MR 1.324 1.101 1.591 0.003  
    MR-Egger 1.462 1.105 1.933 0.008 0.355 
 GWAS restricted 56 3.6 Conventional MR 1.350 1.067 1.709 0.012  
    MR-Egger 1.558 1.005 2.416 0.047 0.447 
SAO GWAS threshold 75 6.4 Conventional MR 1.090 0.925 1.284 0.303   
    MR-Egger 1.211 0.940 1.559 0.138 0.285 
 GWAS threshold(MRPRESSO) 74 6.4 Conventional MR 1.109 0.960 1.281 0.161  
    MR-Egger 1.164 0.930 1.456 0.185 0.581 
  Steiger filter 1 67 5.9 Conventional MR 1.136 0.978 1.319 0.096  
    MR-Egger 1.203 0.960 1.506 0.108 0.502 
 Steiger filter 2 61 5.6 Conventional MR 1.149 0.987 1.337 0.074  
    MR-Egger 1.194 0.951 1.498 0.126 0.653 
 GWAS restricted 56 3.6 Conventional MR 1.216 0.992 1.490 0.060  
    MR-Egger 1.438 0.991 2.087 0.056 0.291 
 GWAS restricted (MRPRESSO) 55 3.6 Conventional MR 1.243 1.030 1.502 0.024  
      MR-Egger 1.393 0.985 1.969 0.061 0.443 
CE GWAS threshold 75 6.4 Conventional MR 0.986 0.838 1.161 0.866  
    MR-Egger 1.160 0.904 1.490 0.244 0.095 
  Steiger filter1 67 5.9 Conventional MR 1.001 0.842 1.190 0.995  
    MR-Egger 1.122 0.865 1.456 0.384 0.247 
 Steiger filter 2 61 5.6 Conventional MR 1.000 0.837 1.195 0.999  
    MR-Egger 1.135 0.871 1.478 0.349 0.208 
 GWAS restricted 56 3.6 Conventional MR 1.020 0.802 1.296 0.874  
        MR-Egger 1.437 0.931 2.217 0.101 0.065 
* Includes all SNPs that associates with a trait and have a p < 5  10-8  
† Includes all SNPs with r2 values with their traits higher than the other 2 traits 
‡ Includes all SNPs with r2 values with their traits higher and the difference is significant (p<0.05) compared to each of the other 2 traits 
§Includes that associates with a trait and have a p < 5  10-8 and don’t associate with any of the other 2 traits p > 5  10-8 
GWAS, Genome-Wide Association Study; IS, Ischemic Stroke; SAO, Small Artery Occlusion Stroke; CE, Cardio-Embolic Stroke 
Supplemental Table V. Sensitivity Mendelian randomization analyses of HDL cholesterol with ischemic stroke and subtypes. 
 
            95% CI     
Trait Instrument N Variance Method OR lower limit upper limit p p-intercept 
IS GWAS threshold* 85 5.9 Conventional MR 0.915 0.831 1.007 0.0706   
      MR-Egger 1.013 0.869 1.181 0.8672 0.096 
  GWAS threshold (MRPRESSO) 84 5.9 Conventional MR 0.930 0.857 1.008 0.0776   
      MR-Egger 0.994 0.874 1.132 0.9334 0.192 
  Steiger filter 1† 77 5.0 Conventional MR 0.896 0.807 0.994 0.0388   
      MR-Egger 0.993 0.844 1.169 0.9325 0.110 
  Steiger filter 1 (MRPRESSO) 76 4.9 Conventional MR 0.913 0.838 0.995 0.0372   
      MR-Egger 0.976 0.853 1.117 0.7217 0.210 
  Steiger filter 2‡ 50 4.2 Conventional MR 0.905 0.822 0.998 0.0447   
      MR-Egger 0.954 0.822 1.108 0.5389 0.365 
  GWAS restricted§ 50 1.9 Conventional MR 0.931 0.812 1.067 0.3053   
      MR-Egger 1.182 0.917 1.522 0.1962 0.031 
LAA GWAS threshold 85 5.9 Conventional MR 0.925 0.745 1.148 0.480   
      MR-Egger 1.240 0.878 1.751 0.221 0.035 
  Steiger filter 1 77 5.0 Conventional MR 0.865 0.688 1.089 0.218   
      MR-Egger 1.217 0.850 1.741 0.283 0.017 
  Steiger filter 2 50 4.2 Conventional MR 0.967 0.783 1.196 0.760   
      MR-Egger 1.063 0.762 1.482 0.720 0.471 
  GWAS restricted 50 1.9 Conventional MR 0.988 0.690 1.413 0.947   
      MR-Egger 2.060 0.991 4.283 0.053 0.026 
  GWAS restricted (MRPRESSO) 48 1.9 Conventional MR 1.090 0.799 1.487 0.586   
      MR-Egger 1.830 0.965 3.473 0.064 0.072 
SAO GWAS threshold 85 5.9 Conventional MR 0.788 0.670 0.927 0.004   
      MR-Egger 0.868 0.674 1.119 0.276 0.330 
  GWAS threshold (MRPRESSO) 84 5.9 Conventional MR 0.806 0.698 0.931 0.003   
      MR-Egger 0.847 0.675 1.061 0.149 0.577 
  Steiger filter 1 77 5.0 Conventional MR 0.803 0.678 0.952 0.011   
      MR-Egger 0.876 0.676 1.136 0.320 0.385 
  Steiger filter 1 (MRPRESSO) 76 4.9 Conventional MR 0.824 0.707 0.961 0.014   
      MR-Egger 0.856 0.677 1.082 0.193 0.679 
  Steiger filter 2 50 4.2 Conventional MR 0.807 0.685 0.951 0.010   
      MR-Egger 0.869 0.680 1.111 0.263 0.422 
  GWAS restricted 50 1.9 Conventional MR 0.824 0.652 1.043 0.107   
      MR-Egger 0.939 0.630 1.400 0.759 0.427 
CE GWAS threshold 85 5.9 Conventional MR 0.901 0.782 1.038 0.150   
      MR-Egger 0.945 0.749 1.194 0.637 0.612 
  Steiger filter 1 77 5.0 Conventional MR 0.901 0.772 1.052 0.186   
      MR-Egger 0.875 0.681 1.123 0.294 0.766 
  Steiger filter 2 50 4.2 Conventional MR 0.892 0.749 1.062 0.201   
      MR-Egger 0.852 0.645 1.125 0.258 0.672 
  GWAS restricted 50 1.9 Conventional MR 0.991 0.772 1.273 0.946   
      MR-Egger 1.267 0.727 2.208 0.403 0.332 
* Includes all SNPs that associates with a trait and have a p < 5  10-8  
† Includes all SNPs with r2 values with their traits higher than the other 2 traits 
‡ Includes all SNPs with r2 values with their traits higher and the difference is significant (p<0.05) compared to each of the other 2 traits 
§Includes that associates with a trait and have a p < 5  10-8 and don’t associate with any of the other 2 traits p > 5  10-8 
GWAS, Genome-Wide Association Study; IS, Ischemic Stroke; SAO, Small Artery Occlusion Stroke; CE, Cardio-Embolic Stroke 
 
  
Supplemental Table VI. Sensitivity Mendelian randomization analyses of triglycerides with ischemic stroke and subtypes. 
 
      95% CI   
Trait Instrument N Variance Method OR lower limit upper limit p p-intercept 
IS GWAS threshold* 51 4.6 Conventional MR 0.978 0.887 1.079 0.659  
    MR-Egger 0.972 0.824 1.146 0.733 0.921 
 Steiger filter 1† 39 4.0 Conventional MR 1.039 0.940 1.149 0.452  
    MR-Egger 0.967 0.824 1.134 0.676 0.253 
 Steiger filter 2‡ 21 3.2 Conventional MR 0.995 0.888 1.114 0.926  
    MR-Egger 1.028 0.853 1.238 0.775 0.666 
 GWAS restricted§ 16 1.2 Conventional MR 1.054 0.875 1.270 0.580  
    MR-Egger 1.016 0.732 1.411 0.923 0.792 
LAA GWAS threshold 51 4.6 Conventional MR 0.991 0.782 1.254 0.938  
    MR-Egger 0.693 0.475 1.011 0.057 0.021 
 Steiger filter 1 39 4.0 Conventional MR 0.996 0.800 1.240 0.971  
    MR-Egger 0.789 0.557 1.119 0.184 0.094 
 Steiger filter 2 21 3.2 Conventional MR 0.916 0.716 1.172 0.486  
    MR-Egger 0.978 0.651 1.468 0.914 0.693 
 GWAS restricted 16 1.2 Conventional MR 1.239 0.826 1.857 0.300  
    MR-Egger 0.974 0.479 1.983 0.943 0.420 
SAO GWAS threshold 51 4.6 Conventional MR 1.024 0.856 1.224 0.794  
    MR-Egger 1.134 0.842 1.526 0.408 0.401 
 Steiger filter 1 39 4.0 Conventional MR 1.052 0.869 1.275 0.602  
    MR-Egger 1.137 0.838 1.543 0.411 0.525 
 Steiger filter 2 21 3.2 Conventional MR 1.019 0.807 1.288 0.872  
    MR-Egger 1.268 0.871 1.845 0.215 0.151 
 GWAS restricted 16 1.2 Conventional MR 0.900 0.627 1.291 0.566  
    MR-Egger 1.194 0.633 2.250 0.585 0.288 
CE GWAS threshold 51 4.6 Conventional MR 1.017 0.857 1.207 0.846  
    MR-Egger 1.128 0.848 1.501 0.408 0.374 
 Steiger filter 1 39 4.0 Conventional MR 1.062 0.857 1.315 0.584  
    MR-Egger 1.053 0.746 1.487 0.769 0.953 
 Steiger filter 2 21 3.2 Conventional MR 1.032 0.838 1.269 0.769  
    MR-Egger 1.016 0.723 1.428 0.925 0.915 
 GWAS restricted 16 1.2 Conventional MR 0.904 0.605 1.350 0.622  
    MR-Egger 1.141 0.558 2.330 0.718 0.438 
* Includes all SNPs that associates with a trait and have a p < 5  10-8  
† Includes all SNPs with r2 values with their traits higher than the other 2 traits 
‡ Includes all SNPs with r2 values with their traits higher and the difference is significant (p<0.05) compared to each of the other 2 traits 
§Includes that associates with a trait and have a p < 5  10-8 and don’t associate with any of the other 2 traits p > 5  10-8 
GWAS, Genome-Wide Association Study; IS, Ischemic Stroke; SAO, Small Artery Occlusion Stroke; CE, Cardio-Embolic Stroke 
 
 
  
Members of the Stroke Genetics Network (SiGN) 
 
Administrative: 
Steven J. Kittner, MD, MPH (chair; Department of Neurology, University of Maryland School 
of Medicine and Veterans Affairs Maryland Health Care System, Baltimore, MD, USA);  
Cameron A. Dell, BS (Department of Neurology, University of Maryland School of Medicine, 
Baltimore, MD, USA);  
Dale M. Gamble, MHSc, CCRP (Department of Neurology, Mayo Clinic, Jacksonville, FL, 
USA);  
Mary J. Sparks, RN, BSN (Department of Neurology, University of Maryland School of 
Medicine, Baltimore, MD, USA) 
 
Steering/PIs of Discovery Studies: 
Donna K. Arnett, PhD, MSPH (Department of Epidemiology, School of Public Health, 
University of Alabama at Birmingham, Birmingham, AL, USA);  
Oscar Benavente, MD, FRCP (Department of Neurology, University of British Columbia, 
Vancouver, British Columbia, Canada);  
John W. Cole, MD, MS (Department of Neurology, University of Maryland School of Medicine 
and Veterans Affairs Maryland Health Care System, Baltimore, MD, USA);  
Martin Dichgans, MD (Institute for Stroke and Dementia Research, Klinikum der Universität 
München, Ludwig-Maximilians University, Munich, Germany; Munich Cluster for Systems 
Neurology (SyNergy), Munich, Germany); 
Raji P. Grewal, MD (Neuroscience Institute, Saint Francis Medical Center, School of Health 
and Medical Sciences, Seton Hall University, South Orange, New Jersey, USA);  
Christina Jern, MD, PhD (Institute of Biomedicine, the Sahlgrenska Academy at University of 
Gothenburg, Gothenburg, Sweden); 
Jordi Jiménez Conde, MD, PhD (Department of Neurology, Neurovascular Research Group 
(NEUVAS) IMIM-Hospital del Mar (Institut Hospital del Mar d’Investigacions Mèdiques), 
Universitat Autonoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain);  
Julie A. Johnson, PharmD (Department of Pharmacotherapy and Translational Research and 
Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, 
USA; Division of Cardiovascular Medicine, College of Medicine, University of Florida, 
Gainesville, FL, USA);  
Jin-Moo Lee, MD, PhD (Stroke Center, Department of Neurology, Washington University 
School of Medicine, St. Louis, MO, USA);  
Christopher Levi, MBBS, BMed Sci, FRACP (John Hunter Hospital, Hunter Medical Research 
Institute and University of Newcastle, NSW, Australia);  
Arne Lindgren, MD PhD (Department of Clinical Sciences Lund, Neurology, Lund University, 
Lund, Sweden; Department of Neurology and Rehabilitation Medicine, Neurology, Skåne, 
University Hospital, Lund, Sweden);  
Hugh S. Markus, DM (Department of Clinical Neurosciences, University of Cambridge, 
Cambridge, UK);  
Olle Melander, MD, PhD (Lund University, Department of Clinical Sciences, Malmö 
University Hospital, Malmö, Sweden);  
James F. Meschia, MD (Department of Neurology, Mayo Clinic, Jacksonville, FL, USA);  
Kathryn Rexrode, MD, MPH (Brigham and Women's Hospital, Boston, MA, USA);  
Jonathan Rosand, MD, MSc (Program in Medical and Population Genetics, Broad Institute of 
MIT and Harvard, Cambridge MA, USA; Department of Neurology and Center for Human 
Genetic Research, Massachusetts General Hospital, Boston, MA, USA; Department of 
Neurology, Harvard Medical School, Boston, MA, USA); 
Peter M. Rothwell, FMedSci (Stroke Prevention Research Unit, Nuffield Department of 
Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK);  
Tatjana Rundek, MD, PhD, FANA (Department of Neurology, Miller School of Medicine, 
University of Miami, Miami, FL, USA);  
Ralph L. Sacco, MD, MS, FAHA, FAAN, FANA (Department of Neurology, Miller School of 
Medicine, University of Miami, Miami, FL, USA);  
Reinhold Schmidt, MD (Department of Neurology, Clinical Division of Neurogeriatrics, 
Medical University Graz, Graz, Austria);  
Pankaj Sharma, MD, PhD, FRCP (Institute of Cardiovascular Research, Royal Holloway 
University of London (ICR2UL), Egham, UK; St Peter’s and Ashford Hospitals, UK);  
Agnieszka Slowik, MD, PhD (Department of Neurology, Jagiellonian University Medical 
College, Krakow, Poland);  
Cathie LM Sudlow, DPhil, FRCP(E) (Centre for Clinical Brain Sciences & Institute of Genomic 
and Molecular Medicine, University of Edinburgh, UK);  
Vincent Thijs, MD, PhD (KU Leuven - University of Leuven, Department of Neurosciences, 
Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), 
Leuven, Belgium; VIB, Vesalius Research Center, Laboratory of Neurobiology, Leuven, 
Belgium; University Hospitals Leuven, Department of Neurology, Leuven, Belgium);  
Sylvia Wassertheil-Smoller, PhD (Department of Epidemiology and Population Health, Albert 
Einstein College of Medicine, Bronx, NY, USA);  
Daniel Woo, MD, MS (University of Cincinnati College of Medicine, Cincinnati, OH, USA);  
Bradford B. Worrall, MD, MSc (Departments of Neurology and Public Health Sciences, 
University of Virginia, Charlottesville, VA, USA) 
PIs of Control Studies: 
Rebecca D. Jackson, MD (Division of Endocrinology, Diabetes and Metabolism, Department 
of Internal Medicine and the Center for Clinical and Translational Science, The Ohio State 
University, Columbus, OH); 
Martina Müller-Nurasyid, PhD (Institute of Genetic Epidemiology, Helmholtz Zentrum 
München – Germany; Research Center for Environmental Health, Neuherberg, Germany; 
Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany; 
DZHK (German Centre for Cardiovascular Research), partner site Munich; Heart Alliance, 
Munich, Germany);  
Mike A. Nalls, PhD (Laboratory of Neurogenetics, National Institute on Aging, National 
Institutes of Health, Bethesda, MD, USA);  
Marta Ribasés, PhD, BSc (Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and 
Addictions, 
Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, 
Spain; Department of Psychiatry, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 
Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain);  
David R. Weir, PhD (Survey Research Center, University of Michigan, Ann Arbor, MI, USA) 
Data Management: 
Patrick F. McArdle, PhD (chair; Department of Medicine and Program for Personalized and 
Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD);  
Tushar Dave, MS (Department of Medicine and Program for Personalized and Genomic 
Medicine, University of Maryland School of Medicine, Baltimore, MD, USA) 
Analysis: 
Braxton D. Mitchell, PhD, MPH (chair; Division of Endocrinology, Diabetes and Nutrition, 
University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research and 
Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA);  
Yu-Ching Cheng, PhD (Department of Medicine, University of Maryland School of Medicine, 
Baltimore, MD, USA);  
Paul I.W. de Bakker, PhD (Department of Medical Genetics, University Medical Center 
Utrecht, Utrecht, The Netherlands; Department of Epidemiology, University Medical Center 
Utrecht, Utrecht, The Netherlands);  
Myriam Fornage, PhD (Institute of Molecular Medicine, University of Texas Health Science 
Center at 
Houston, Houston, TX, USA);  
Cathy C. Laurie, PhD (Department of Biostatistics, University of Washington, Seattle, WA, 
USA);  
Ani Manichaikul, PhD (Center for Public Health Genomics, Biostatistics Section, Department 
for Public Health Sciences, University of Virginia, Charlottesville, VA, USA);  
Jeffrey R. O’Connell, DPhil (Division of Endocrinology, Diabetes and Nutrition, University of 
Maryland School of Medicine, Baltimore, MD, USA);  
Sara L. Pulit, BA (Department of Medical Genetics, Institute for Molecular Medicine, 
University Medical Center Utrecht, Utrecht, The Netherlands);  
Stephen S. Rich, PhD (Center for Public Health Genomics, University of Virginia, 
Charlottesville, VA, USA);  
Quenna Wong, MS (Department of Biostatistics, University of Washington, Seattle, WA, 
USA);  
Huichun Xu, MD, PhD (Department of Medicine, University of Maryland School of Medicine, 
Baltimore, MD, USA) 
Phenotype: 
James F. Meschia, MD (co-chair; Department of Neurology, Mayo Clinic, Jacksonville, FL, 
USA);  
Bradford B. Worrall, MD, MSc (co-chair; Departments of Neurology and Public Health 
Sciences, University of Virginia, Charlottesville, VA, USA);  
Hakan Ay, MD (AA Martinos Center for Biomedical Imaging, Department of Radiology, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Stroke Service, 
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, 
MA, USA);  
Robert D. Brown Jr., MD, MPH (Department of Neurology, Mayo Clinic, Rochester, MN, 
USA) 
Imaging: 
Jonathan Rosand, MD, MSc (chair; Program in Medical and Population Genetics, Broad 
Institute of MIT and Harvard, Cambridge MA, USA; Department of Neurology and Center for 
Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA; Department of 
Neurology, Harvard Medical School, Boston, MA, USA);   
Natalia S. Rost, MD, MPH (Stroke Division, Department of Neurology, Massachusetts General 
Hospital, Harvard Medical School, Boston, MA 02114);  
Ona Wu, PhD (Athinoula A. Martinos Center for Biomedical Imaging, Department of 
Radiology, Massachusetts General Hospital, Charlestown, MA, USA; Department of 
Radiology, Harvard Medical School, Boston, MA, USA) 
Publication: 
Kathryn Rexrode, MD, MPH (chair Brigham and Women's Hospital, Boston, MA, USA);  
Tatjana Rundek, MD, PhD, FANA (prior chair; Department of Neurology, Miller School of 
Medicine, University of Miami, Miami, FL, USA);  
Agnieszka Slowik, MD, PhD (prior co-chair; Department of Neurology, Jagiellonian 
University Medical College, Krakow, Poland);   
Hakan Ay, MD (AA Martinos Center for Biomedical Imaging, Department of Radiology, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Stroke Service, 
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, 
MA, USA);  
Oscar R. Benavente, MD, FRCP (Department of Neurology, University of British Columbia, 
Vancouver, British Columbia, Canada);  
Steve Bevan, PhD (Department of Clinical Neurosciences, University of Cambridge, 
Cambridge, UK);  
Katrina Gwinn, MD (National Institute of Neurological Disorders and Stroke, National 
Institutes of Health, Bethesda, MD, USA);  
Steven J. Kittner, MD, MPH (chair; Department of Neurology, University of Maryland School 
of Medicine and Veterans Affairs Maryland Health Care System, Baltimore, MD, USA);  
Jin-Moo Lee, MD, PhD (Stroke Center, Department of Neurology, Washington University 
School of 
Medicine, St. Louis, MO, USA);  
Patrick F. McArdle, PhD (Department of Medicine and Program for Personalized and Genomic 
Medicine, University of Maryland School of Medicine, Baltimore, MD);   
James F. Meschia, MD (Department of Neurology, Mayo Clinic, Jacksonville, FL, USA);  
Braxton D. Mitchell, PhD, MPH (Division of Endocrinology, Diabetes and Nutrition, 
University of Maryland School of Medicine, Baltimore, MD, USA; Geriatric Research and 
Education Clinical Center, Veterans Administration Medical Center, Baltimore, MD, USA);  
Jonathan Rosand, MD, MSc (Program in Medical and Population Genetics, Broad Institute of 
MIT and Harvard, Cambridge MA, USA; Department of Neurology and Center for Human 
Genetic Research, 
Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Harvard 
Medical School, Boston, MA, USA);    
Sylvia Wasssertheil-Smoller, PhD (Department of Epidemiology and Population Health, Albert 
Einstein College of Medicine, Bronx, NY, USA);  
Daniel Woo, MD, MS (University of Cincinnati College of Medicine, Cincinnati, OH, USA);  
Bradford B. Worrall, MD, MSc (Departments of Neurology and Public Health Sciences, 
University of Virginia, Charlottesville, VA, USA) 
CIDR: 
Kimberly F. Doheny, PhD (Center for Inherited Disease Research, Institute of Genetic 
Medicine, Johns Hopkins School of Medicine, Baltimore, MD) 
NINDS staff: 
Roderick Corriveau, PhD (National Institutes of Health, Bethesda, MD, USA);  
Katrina Gwinn, MD (National Institute of Neurological Disorders and Stroke, National 
Institutes of Health, Bethesda, MD, USA) 
  
References 
 
1. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al; Global Lipids 
Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat 
Genet. 2013;45:1274-1283 
2. NINDS Stroke Genetics Network (SiGN), International Stroke Genetics Consortium 
(ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): A genome-wide 
association study. Lancet Neurol. 2016;15:174-184 
 
 
Ischemic Stroke
LDL cholesterol 
LDLR
HMGCR
PCSK9
NPC1L1
HDL cholesterol
CETP
Large Artery Atherosclerosis   
LDL cholesterol 
LDLR
HMGCR
PCSK9
NPC1L1
HDL cholesterol
CETP
Small Artery Occlusion   
LDL cholesterol
LDLR
HMGCR
PCSK9
NPC1L1
HDL cholesterol
CETP
Cardio−embolic
LDL cholesterol 
LDLR
HMGCR
PCSK9
NPC1L1
HDL cholesterol
CETP
Controls/Cases
32473/16851
32473/2410
32473/3186
32473/3186
0.1 1 3
OR
0.78
0.70
1.03
0.61
0.94
0.66
1.04
0.83
0.18
0.91
0.75
0.41
0.75
0.22
0.88
0.83
0.47
1.68
1.88
0.91
[95% CI]
[0.63; 0.96]
[0.50; 0.99]
[0.82; 1.30]
[0.37; 0.99]
[0.88; 1.00]
[0.45; 0.98]
[0.38; 2.86]
[0.51; 1.38]
[0.06; 0.53]
[0.77; 1.09]
[0.45; 1.25]
[0.21; 0.81]
[0.48; 1.16]
[0.08; 0.56]
[0.78; 1.00]
[0.59; 1.16]
[0.20; 1.12]
[1.10; 2.56]
[0.76; 4.71]
[0.81; 1.03]
p−value
0.019
0.042
0.794
0.046
0.049
0.039
0.934
0.477
0.002
0.303
0.274
0.010
0.200
0.002
0.054
0.280
0.088
0.016
0.174
0.133
